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Abstract 
 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and a 
major cause of neurological disability in young adults. There is robust evidence showing that 
immune-mediated axon damage is a major cause for progression of permanent neurological 
deficits. Previously our lab used in vivo imaging in a mouse model of MS to identify focal axonal 
degeneration as a correlate of inflammatory axon loss. It is characterized as a sequential 
process, beginning with focal swellings and progressing to multi-focal axon fragmentation. This 
process is observed in axons with intact myelin sheaths and its early stages can recover 
spontaneously. We were able to show that elevated calcium levels influence the axonal fate to 
degenerate in EAE lesions, however the degenerative process triggered via elevated calcium is 
not understood. In my thesis work, I now investigated how cytoplasmic calcium accumulations 
mediate neurodegeneration in experimental autoimmune encephalomyelitis (EAE), an animal 
model of MS. We assessed the effect of delayed Wallerian degeneration genotypes (ΔNLS-
Wlds and Sarm1 knock-out), which did not result in a reduction of clinical disability or reduction 
of axonal fragmentation in acute or chronic lesions in vivo. The inhibition of Calpain, a calcium-
activated protease, however reduced axonal fragmentation in acute lesions in vivo. These 
results indicate that the degeneration of axons in neuroinflammatory lesions is distinct from 
Wallerian degeneration and opens up possibilities for neuroprotective therapies targeting the 
calcium-calpain axis.  
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Zusammenfassung 
 
Die Multiple Sklerose (MS) ist eine chronische Entzündung des zentralen Nervensystems und 
ein Hauptauslöser neurologischer Behinderung bei jungen Menschen. Wissenschaftliche 
Studien zeigen, dass die immunvermittelte Nervenschädigung eine der Ursachen für das 
Voranschreiten unwiederbringlicher neurologischer Funktionausfälle ist.  
Unser Labor hat in vorherigen intravitalen Mikroskopiestudien in einem Mausmodel der 
Multiplen Sklerose die Fokale Axondegeneration (FAD) als Korrelat von entzündungsbedingtem 
Axonverlust erkannt. FAD ist ein sequenzieller Prozess, der mit fokalen Schwellungen beginnt 
und bis zur multifokalen Axonfragmentierung fortschreitet. Dieser Prozess wird auch in Axonen 
mit intakten Myelinschichten beobachtet und die frühen FAD Stadien haben das Potential, sich 
spontan zu erholen. Wir konnten zeigen, dass erhöhtes intrazelluläres Kalzium die 
anschließende Fragmentation der Axone begünstigt. Jedoch wird der degenerative Prozess, 
der durch den pathologischen Anstieg an intrazellulärem Kalzium in den betroffenen Axonen 
ausgelöst wird, bislang noch nicht vollständig verstanden.  
In meiner Arbeit beschäftige ich mich mit den Mechanismen der Axondegeneration ausgelöst 
durch zytoplasmatischen Kalziumanstieg in Experimenteller Autoimmuner Enzephalomyelitis 
(EAE), einem Tiermodell der Multiplen Sklerose. Zunächst haben wir die Wirkung von 
genetischen Mutationen (ΔNLS-Wlds and Sarm1 knock-out) untersucht, die die Wallersche 
Degeneration nach einer traumatischen Nervenverletzung verzögern. Wir konnten jedoch keine 
Verminderung der klinischen Beeinträchtigung oder axonaler Fragmentation in akuten oder 
chronischen EAE Läsionen feststellen. Die Inhibierung von Calpain, einer durch Kalzium 
aktivierten Protease, zeigte eine Veringerung der axonalen Fragmentation in akuten Läsionen in 
vivo. Diese Ergebnisse weisen darauf hin, dass die Degeneration der Axone in 
neuroinflammatorischen Läsionen sich von Wallerscher Degeneration unterscheidet. Darüber 
hinaus eröffnet die erfolgreiche pharmakologische Reduzierung der Fragmentation neue 
Möglichkeiten für neuroprotektive Therapien, die an der Kalcium-Calpain-Achse ansetzen.  
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1 Introduction 
1.1 Multiple Sclerosis (MS) 
1.1.1 Epidemiology and etiology 
 
“We all look very good and we look healthy, but it’s the symptoms we deal with on a daily basis 
that people don’t get”.  
Carol Cooke. 2016 
Multiple sclerosis is an unpredictable disease; every patient experiences different symptoms. 
This inspired Paralympian Carol Cooke, who was diagnosed with multiple sclerosis (MS) 20 
years ago, to sit together with neurologists, physiotherapists, bike mechanics and other MS 
patients to develop a special racing bike for the MS Melbourne Cycle that mirrors common MS 
symptoms. For example, the wheels were weighed down to resemble fatigue, the design of the 
handlebars lead to a pin and needle sensation while riding or the gears were designed to slip 
unpredictably. In that way, the rider is not able to control the speed, direction or momentum of 
its bike, in analogy to a MS patient, who has to battle loss of motor control. Since it is not 
obvious to outsiders, the bike became a perfect metaphor for what MS patients have to go 
through every day. With fundraising campaigns like this, which are organized by charity 
organization and MS associations around the world, awareness has risen significantly in the 
past years. 
MS is a chronic inflammatory disease of the central nervous system (CNS) with a presumed 
autoimmune etiology. The mean age of onset is 30 years, but MS can be also diagnosed in 
childhood or after the age of 60. It affects women three times more than men (Ribbons et al., 
2017) and is considered to be one of the major causes of neurological disability and premature 
retirement among young adults (Flachenecker et al., 2008, 2017). Since there is no curative 
treatment available, MS causes a considerable healthcare, social and family burden (Kobelt et 
al., 2017). With campaigns like the above-mentioned, awareness and therefore funding is being 
raised for research in order to get a better understanding of the underlying causes and to 
develop more effective possibilities of treatment.  
Until this very day, MS remains a disease with a not entirely known etiology. It has been 
suggested that the disease is triggered in people having a genetic predisposition by certain still 
unknown environmental factors. This assumption is supported by migration studies. The 
prevalence rate of immigrants tends to be similar to that of the indigenous population, especially 
when the migration occurred before puberty (Gale and Martyn, 1995). With the introduction of 
Next Generation Sequencing and bioinformatics it was possible to identify that approximately 
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1/3 of the genetic susceptibilities to MS are localized to the major histocompatibility complex 
(MHC) class II (Hollenbach and Oksenberg, 2015) which would explain the autoimmune character 
of the disease. Twin and sibling studies confirmed the finding that genes are responsible for 30 
% of the total disease risk.  
Several environmental factors are found to contribute to the risk of developing MS. In studies, a 
connection between MS and vitamin D deficiency has been found as well as to reduced 
exposure to sunlight and ultraviolet radiation (DeLuca and Plum, 2017), smoking (Degelman and 
Herman, 2017) and obesity (Novo and Batista, 2017). An infection with EBV appears to be 
closely associated with MS and it has been proposed that MS development might be a result of 
failed viral clearance (Burnard et al., 2017). This complexity in disease etiology leads to a 
diagnostic challenge, despite the huge progress in diagnostic methods.  
  
Introduction 
 
 
3 
 
1.1.2 MS Pathology 
 
MS is a chronic disease with a thousand faces. Every patient has a unique set of clinical 
manifestations, regarding type of symptom during a relapse and the duration and frequency of 
such relapses. The disease course of MS is for a single patient not predictable. A patient, who 
presents with optic neuritis (ON) might have only this Clinically Isolated Syndrome (CIS). 
However, if symptoms reappear in another functional system and at a different time point, the 
CIS becomes the onset of MS. Therefore, the diagnosis of MS remains a challenge.  
Although the first recorded description of MS dates already back to 1421 (Medaer, 1979), it was 
still not identified as a separate disease by the German pathologist Friedrich von Frerichs until 
1849. The “father of neurology” Jean Martin Charcot was the first one, who collected several 
cases and demonstrated in a lecture series at the La Salpétrière hospital the connection 
between the diverse symptoms and the underlying pathological changes that lead to the 
development of the first diagnostic criteria for MS: nystagmus, ataxia and dysarthria (Charcot 
triad) (Milo and Miller, 2014). The diagnostic criteria were since then revised several times and 
adapted to the continuously improvements of diagnostic methods and knowledge about the 
disease in general. Nowadays the 2017 revision of the McDonald diagnostic criteria (Thompson 
et al., 2017) is used, which incorporate the use of MRI imaging and cerebrospinal fluid analysis 
as diagnostic tools. In short, for a MS diagnosis it needs to be demonstrated that inflammatory 
lesions are disseminating in space and in time, along with exclusion of an alternative diagnosis.  
The histopathological hallmarks of MS are the presence of scattered demyelinated plaques that 
consist of inflammatory mononuclear cells, damaged axons and gliosis. This pathological 
activity translates to a wide variety of possible neurological symptoms that affect different parts 
of the CNS. Common symptoms are paresthesia or numbness, motor weakness, monocular 
visual disturbance, diplopia, incoordination, gait disturbances, dizziness and vertigo. This can 
be accompanied by symptoms like fatigue, spasticity, ataxia, nystagmus, sensory loss, 
neuropathic pain, urinary urgency or retention, sexual dysfunction, depression or other 
emotional changes, heat intolerance, Lhermitte`s phenomenon, cognitive dysfunction and more 
(Milo and Miller, 2014). A relapse is defined as a clinical symptom that is present for at least 24 
hours and is not explainable due to an infection or change of body temperature (Uhthoff-
phenomenon). The interval between two relapses should be at least 30 days to classify them as 
independent (Gold, 2014).  
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1.1.3 Clinical Course of MS 
 
Although every patient experiences a different clinical course, based on the relapse frequency 
and grade of recovery four major disease types are recognized: 
 
 Clinically isolated syndrome (CIS): 
In a CIS, a patient presents for the first time with a - for a demyelinating event typical - clinical 
symptom without evidence for previous episodes of demyelination (Gold, 2014; Miller et al., 
2012). After the CIS the disability may still persist, or the patient has a complete remission of 
clinical symptoms (see Figure 1A). Initially CIS was not included in the MS clinical descriptions. 
Depending on in which part of the CNS the CIS occurs, the conversion to clinically definite MS 
is reported to happen in 65 % of patients (in case of ON), 60 % of patients (in case of CIS in 
brain stem) or 61 % of patient (in case of CIS in spinal cord) (Fisniku et al., 2008; Miller et al., 
2012). CIS patients that are treated with MS disease-modifying agents show reduced MRI 
activity and develop less frequently a second exacerbation which would be the fulfilling criteria 
to MS diagnosis (Comi et al., 2009).  
In some cases, patients are presented with unusual MRI activity with absence of clinical signs 
or symptoms. This radiologically isolated syndrome (RIS) is not considered a distinct MS 
phenotype since there is no clinical evidence of demyelinating disease (Okuda et al., 2009).   
 
 Relapsing-remitting MS (RRMS): 
Clinically MS starts in 80 – 85 % of patients as RRMS (Healy and Liguori, 2012). Relapsing-
onset patients are more likely to be female (gender ratio 2-3 females to 1 male) and the mean 
age at onset is 25 – 35 years (Confavreux and Vukusic, 2006). During RRMS, clearly defined 
attacks of new or recurrent neurological symptoms and signs with full or partial recovery are 
observable. There is a lack of disease progression between disease relapses. At different points 
in time, the clinical course may be characterized as either active (increased MRI activity or 
relapses) or inactive. Following relapse, the clinical symptoms may disappear completely, or the 
patients exhibits a worsening of disability level (see Figure 1B). Relapsing forms of MS are 
defined by inflammatory attacks. Relapsing MS patients tend to develop more brain lesions with 
a high density of inflammatory cells (plaque or scars) that can be visualized in MRI scans. 
These findings explain the nature of the episodic bouts of deficits like visual problems, 
spasticity, cognitive and memory problems. 
Introduction 
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 Secondary-progressive MS (SPMS): 
After a period of 10 years, in 50% of patients that were initially diagnosed with RRMS the 
symptoms worsen gradually over time with or without relapses. Therefore, this form is called 
secondary-progressive MS (SPMS). The transition between RRMS and SPMS is unpredictable 
and the diagnosis of SPMS is made retrospectively. To be defined as a chronic progressive 
course the neurological deficits are continuously worsening and accumulating over a period of 
at least 6 months (Trojano et al., 2003). In Figure 1C a representative course is shown.  
 
 Primary-progressive MS (PPMS): 
In 10 – 15 % of MS patients the disease course is predominantly degenerative from onset on. 
Their neurological symptoms worsen progressively with time. There are no early relapses or 
remissions observable (for a representative course see Figure 1D). Therefore, this type is 
defined as primary-progressive MS (PPMS). During their clinical course PPMS patients can 
show occasional relapses and/or increased MRI activity. They may experience stable not active 
phases, but also active and not active progressive phases that result in a gradual accumulation 
of disability. The numbers of female and male PPMS patients are approximately equal (1-1.5 
female to 1 male). The mean age at first diagnosis is 10 years higher than in relapsing MS 
forms. In contrast to relapsing forms of MS, progressive MS patients develop more spinal cord 
lesions that contain fewer inflammatory cells. The predominance of motor symptoms in 
progressive MS patients is consistent with the increased spinal cord atrophy found in this 
patient group (Healy and Liguori, 2012). 
 
Manifestation of MS is more complex than these 4 classifications suggest. Patients suffering 
from a progressive form of MS might still experience relapses (progressive relapsing MS). This 
is indicated in Figure 1 by superimposed relapses on the progressive course (Figure 1 C and 
D). Based on the MRI activity a progressive disease course can be characterized as active 
(contrast-enhancing lesions or new and unequivocally enlarging T2 lesions) or inactive (no sign 
of MRI activity). Therefore, progression as measured by clinical evaluation and activity 
assessed using MRI are important disease modifiers (Lublin et al., 2013).  
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Figure 1. Representation of possible MS disease courses  
A) Two representative disease courses for CIS. The remission of clinical deficits can be complete (dark blue) 
or incomplete (light blue). B) A representative clinical course for RRMS (red curves): Following a relapse, 
new symptoms may disappear without any increase in neurological disability, or recovery after a relapse 
may be incomplete, thereby worsening the disability level. C) Following RRMS, many patients show a 
constantly increasing disability over time (SPMS: progressive course in green). The progressive course can 
have brief stable periods, may show active lesions (relapses, increased MRI activity) followed either by 
complete or incomplete disability remission. D) Patients may show a continuous worsening of neurological 
function from the onset of symptoms, without earlier signs of relapses or remissions (PPMS: primary 
progressive MS). Inspired by MS disease course overview on My-MS.org (https://my-
ms.org/images/chart_ms_course_2013_665.jpg), based on (Thomson et al. 2017). 
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1.1.3.1 Inflammation 
 
Already early in the disease, there are signs of both neuroinflammation and neurodegeneration 
present. Two competing models exist that debate whether axonal damage is a consequence of 
severe inflammation that results from abnormalities in immune processes outside the CNS 
(outside-in model) or an axonal dysfunction initiates chronic inflammation in the CNS (inside-out 
model). Due to some still unclear initiation mechanism, it is thought that sensitized lymphocytes 
migrate across the damaged BBB (Viglietta et al., 2004), because regulatory T cells fail to 
suppress these effector cells, and/or the overexpression of survival factors overcome the 
apoptosis of autoreactive cells (Shi et al., 2007).  
The complexity of the immune system is then reflected in the high diversity of infiltrating effector 
cells found in MS and EAE lesions. It is thought that the autoimmune pathology seen in MS and 
EAE (Billiau and Matthys, 2001) is mostly driven by auto-reactive T-cells (Fletcher et al., 2010). 
However, there is evidence accumulating that B cells are involved in the disease process as 
well (Lehmann-Horn et al., 2017). They are found in the brain parenchyma and are thought to 
contribute to the compartmentalization of humoral immune response with intrathecal antibody 
production (Romanelli et al., 2016). In a recent study, it was found that the meningeal 
inflammation is preceding parenchymal inflammation at all levels of the spinal cord of MOG35-55-
induced EAE mice, thereby identifying the meninges to be significantly involved in the 
development and propagation of CNS inflammation associated with EAE (Shrestha et al., 
2017). Further research is necessary to fully understand the interaction of CNS and immune 
system during neuroinflammatory, demyelinating diseases.  
 
1.1.3.2 Myelin damage  
 
Active demyelination is a central event in MS. In a detailed immunopathological study, four 
different patterns of demyelination have been recognized in MS (Lassmann et al., 2001). In 
pattern I (macrophage-associated demyelination) the destruction of myelin is induced by toxic 
products of activated macrophages such as reactive species. Pattern II of demyelination is 
characterized by complement mediated lysis of antibody-targeted myelin. This antibody-
mediated demyelination pattern can be found in EAE models that result from sensitization with 
MOG. If demyelinated regions are accompanied by distal oligodendrogliopathy and apoptosis it 
is categorized as pattern III. Lesions with prominent oligodendrocyte degeneration in a small rim 
of periplaque white matter are defined as pattern IV. 
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In EAE models it was demonstrated that the immune cells attack myelin, which is first deformed 
on the myelin sheath surface to bulb-like structures, called myelinosomes. The damage then 
further progresses to the oligodendrocyte soma. Myelinosome formation is found in active 
demyelinating MS lesions as well and can be initiated by anti-myelin antibodies and inhibited by 
complement depletion in EAE model (Romanelli et al., 2016). 
 
1.1.3.3 Axon degeneration 
 
Neuroaxonal damage was already described in early studies of MS but generally thought to be 
a secondary process to the immune-mediated demyelinating attacks. More refined studies of 
MS pathology suggest that axonal damage starts early in MS (Trapp et al., 1998). Diffuse 
histopathological abnormalities, as one example, are present already in early disease stages as 
well in normal-appearing white matter (NAWM) and cortical grey matter, as shown through 
reduction of the axonal integrity marker N-acetyl aspartate (NAA) in proton magnetic 
spectroscopy (Bjartmar et al., 2001; Dutta and Trapp, 2007; Filippi et al., 2003). With 
immunohistochemical stainings against amyloid precursor protein or SMI-32 in biopsies of MS 
patients a correlation of axonal injury and inflammation in MS lesion is detectable (Bitsch et al., 
2000). In non-active, “burned-out” lesions axonal damage is present as well (Kornek et al., 
2000; Lassmann, 2003). 
There are not many reliable tools available that can monitor non-invasively neuronal damage. 
With MRI imaging, lesions with pronounced axonal damage are detected as hypointense T1 
weighed black holes and atrophy in CNS can be observed as well early in disease course 
(Barkhof et al., 2009). In a recent study, serum levels of neurofilament light chains (NFL) are 
proposed to be sensitive and clinically meaningful, non-invasive biomarkers for neuronal 
damage in MS patients (Disanto et al., 2017). NFL are scaffolding proteins unique to neuronal 
cells and serum levels of NFL (sNFL) are increased in patients suffering from acute brain and 
spinal cord injury, but as well in patients with MS, ALS and other neurodegenerative disorders. 
In spinal cord samples of patients with SPMS a significant reduction of axonal density as 
measured with immunohistochemical staining against neurofilament is found in both, chronic 
inactive, completely demyelinated plaques and the NAWM, compared to control samples from 
anatomically identical regions (Lovas et al., 2000). Both, acute inflammatory damage and 
chronic diffuse neuronal loss, can contribute to the increase in sNFL levels, which correlate 
highly with relapse and disability state as measured by the expanded disability status scale 
(EDSS). This supports further the possible use of sNFL levels to monitor treatment effects in 
patients. Disanto et al. observed a significant decrease of sNFL in patients under DMT. 
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Increasing evidence indicates that axonal loss correlates best with irreversible neurological 
disability in MS patients. This is even more evident in progressive MS.  
The cause of axon dismantling in MS lesions is still unclear. Several possible mechanisms have 
been recognized to be involved in other disease settings. CNS injury, genetic defects, toxins 
and metabolic disturbances can all lead to axon degeneration. The axon degeneration 
mechanism most discussed is the Wallerian degeneration-like (WD) pathway and the 
neurodegeneration pathway induced via excitotoxicity that will be further discussed below 
(1.2.1. and 1.2.2., respectively). Using in vivo imaging in EAE lesions a novel process of axonal 
degeneration was identified (Nikić et al., 2011): Focal axonal degeneration (FAD) is 
characterized by stable swellings at one or more distinct sites (often at nodes of Ranvier) that 
can disrupt almost simultaneously at several sites along the axons. Morphologically it is very 
similar to other axonal loss pathways like WD, but it has some distinct features: fragmentation 
spreads in both directions, it is even observed in absence of demyelination and its initial phase 
– the swelling of axons – is still able to recover. Axonal abnormalities suggestive of FAD and 
mitochondrial damage were observed within lesion area in MS biopsies as well (Nikić et al., 
2011).  
The mechanism by which immune cells induce axon degeneration is still not fully understood. In 
general, it is assumed that activated T cells migrate into the CNS (Kawakami et al., 2012), 
where they recognize self-antigens in genetically susceptible individuals. During such an attack 
inflammatory cytokine like tumor-necrosis factor alpha (TNF alpha) is secreted by the T cells. 
Resident microglia are activated as well and release chemo- and cytokines into their 
surroundings (Amor et al., 2014; van Noort et al., 2012). Additionally, microglia produce 
excessively reactive nitrogen species (RNS) like NO (Dheen et al., 2007; Witte et al., 2010) 
which can catalyze many degenerative processes in the axons, e.g. the modification of the 
cytoskeleton via nitrosylation of microtubule-associated protein (MAP) 1B (Kapoor et al., 2003; 
Stroissnigg et al., 2007). In MS models, these deficits in axonal transport occur before any 
structural changes to organelles or alterations to microtubule network are observable (Sorbara 
et al., 2014). Microtubule disintegration promotes further axonal transport failure that is coupled 
with NAD and ATP depletion and accumulation of organelles like mitochondria, which become a 
source of reactive oxygen species (ROS). ROS are mediators of oxidative stress and affect 
even further the axonal transport. Application of H2O2 or NO donors is sufficient to induce the 
same mitochondrial changes as observed in EAE lesions and recovery can be achieved by 
neutralization of ROS and RNS in the majority of axons by anti-inflammatory treatment or redox 
scavengers (Nikić et al., 2011; Sorbara et al., 2014). The exact mechanisms are still unknown, 
but all these observations suggest that ROS, RNS and mitochondrial failure play a crucial role in 
triggering downstream axonal disintegration. These impairments of mitochondrial function and 
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axonal transport are observed within axons in MS patients as well (Dutta et al., 2006; Mahad et 
al., 2009). 
1.1.4 Treatment options for MS 
 
Traditionally, MS is considered to be an autoimmune inflammatory disorder of the CNS, in 
which CNS structures, in particular myelin, are attacked by infiltrating immune cells. Consistent 
with this classification of MS as primary autoimmune disease, most of the MS patients present 
with a relapsing-remitting form of MS, in which the inflammatory component dominates the 
disease pathology. Waves of inflammation entering the brain driven by systemic immune 
reaction induce focal demyelinating lesions primarily in white matter. It is assumed that the 
observed atrophy in MS patients is a result of secondary degeneration initiated by an 
inflammatory burden which has become somewhat independent from the initial inflammatory 
assaults. Patients suffering in the first 2 years of frequent, severe relapses are more likely to 
present with a more aggressive form of progressive MS (Scalfari et al., 2010). Therefore, major 
effort was put in revealing the immunological causes and developing pharmacological agents 
that modulate the immune system in order to reduce relapses and disease progression. In the 
past few decades, clinical research made great progress in developing efficient treatment 
options. The currently approved disease-modifying treatments (DMT) are immunomodulatory or 
immunosuppressive therapies that significantly, although not completely reduce the relapse 
frequency and severity (Finkelsztejn, 2014). However, these DMT have limited efficacy in 
preventing the conversion of relapsing MS to the progressive form and show no effect once 
progression has started. Although, a new study introduces Ocrelizumab, a humanized 
monoclonal antibody that selectively depletes CD20-expressing B cells, as an 
immunomodulatory drug in treatment of PPMS (Montalban et al., 2017), its clinical benefit is 
only modest and limited to a selected population of patients (young patients with shorter 
disease duration and a high probability of disease activity). Despite DMT, around 80 % of 
initially RRMS patients convert to SPMS (Kremenchutzky et al., 2006), indicating that these 
treatments fail to halt disease progression. Progressive MS is characterized by prominent 
cortical demyelination and diffuse pathology in NAWM. New active lesions are rare and pre-
existing lesions surrounded by a rim of activated mircoglia expand slowly (Lassmann et al., 
2007). After immunomodulation, it appears that there is a dissociation of relapse suppression 
and disability accumulation, as if the reduction of inflammatory insult unmasks the ongoing, 
steadily progressive neurodegeneration. Besides this, the prognosis in MS is not substantially 
affected by the initial course type (RRMS vs PRMS), but rather the age at disease onset 
correlates with disability progression. The earlier the disease onset, the younger the age at 
reaching disability milestones (Confavreux and Vukusic, 2006). There are several more clinical 
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abnormalities that can not be explained by a solely autoimmune cause of MS. Inflammation 
might by secondary to an underlying neurodegenerative process (inside-out hypothesis). 
Regardless of this chicken or egg situation, it is a fact that disability progression is due to 
neuronal damage and axonal loss, which is in turn a correlate of clinical disability. There is a 
great need for neuroprotective strategies that besides DMT can improve disease management 
and ideally halt the disability progression.  
 
1.1.5 Animal models of MS 
 
Experimental autoimmune encephalomyelitis (EAE) is the most commonly used model for 
studying autoimmune-mediated damage to the CNS. The model is based on the attempts of 
Rivers and his colleagues to reproduce acute disseminated encephalomyelitis in rhesus 
monkeys via intramuscular injections of adult rabbit brain extracts (Rivers et al., 1933) that lead 
to pathological changes accompanied by myelin destruction. The induction protocol was further 
optimized by adding adjuvants composed of mineral oil and heat-killed tuberculosis bacteria to 
the brain emulsions (Kabat et al., 1947). Usually complete Freud’s adjuvant (CFA) and pertussis 
toxin (PTX) is used, that facilitates the development of immune response and the breakdown of 
blood-brain barrier (BBB). Although EAE can be induced in many different species, rodents are 
the species of choice. Different EAE induction protocols were developed, all resulting in different 
disease characteristics regarding immunology and pathology. For instance, in rodents not only 
brain or spinal cord homogenate is used for immunization, but also purified myelin proteins like 
myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein 
(MOG) or peptides of these proteins representing the significant epitopes.  
EAE reflects the autoimmune origin of MS and shares with the human disease many 
pathological features: Similar to MS, EAE animals develop a demyelinating disease that is 
characterized by scattered lesions throughout the CNS and perivascular localization of immune 
cell infiltrations. In these lesions, both in the animal model and the human disease, damage to 
myelin sheaths and axons can be observed. However, unlike MS, EAE can only mimic parts of 
the MS disease course, but not the full disease spectrum, depending on which mode of 
induction is used.  
In the active sensitization models, the disease is induced by immunization with myelin proteins. 
However, in recent studies, also non-myelin derived antigens are used for induction of CNS 
inflammation. (Krishnamoorthy et al., 2009; Mathey et al., 2007) This process results in the 
direct priming of myelin epitope-specific CD4+ T cells in vivo, which migrate to the CNS and 
mediate autoimmune responses. In the passive adoptive EAE model, the capability of activated 
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T-cell subtypes to induce CNS inflammation is deployed. Activated CD4+ T cells are isolated 
from draining lymph nodes of immunized animals, restimulated with the initiating antigen in vitro 
and then reinjected into naïve recipients.  
The rodent’s genetic background has an influence on the induced disease course (Terry et al., 
2016). For the RR-model type SJL/J mice are immunized with MBP-derived peptides, MBP-
reactive T cell clones (Zamvil et al., 1985) or synthetic myelin PLP139-151 peptide. To induce a 
chronic model, C57BL/J mice are immunized with MOG or PLP peptide. For a chronic-relapsing 
disease course Biozzi ABH mice are used (Terry et al., 2016). 
As both the active and passive EAE models are induced by the experimentator, they tend to be 
not suited to study the immunological mechanisms that initiate the disease process, thereby 
reflecting the spontaneous manifestation in MS patients. Therefore, a genetic, “spontaneous” 
EAE model was developed, in which T-cell receptor of encephalitogenic T-cells is transgenically 
expressed that recognizes a CNS antigen, like MOG (Bettelli et al., 2003). These mice develop 
an autoimmune inflammatory demyelinating disease several months after birth that resembles 
conventional EAE models in many ways. Furthermore, a neurotrophic viral injection model for 
MS was developed. Theiler’s murine encephalomyelitis virus injected in rodents induces an 
immune-mediated attack on CNS. Despite the difference of demyelination pattern in mice 
compared to MS patients (Dal et al., 1996), this model still is used for testing new therapies 
since it shows similar clinical manifestation and pathology that is induced by activation of 
immune system.  
Although thanks to this large spectrum of different models, useful insights into the mechanisms 
involved in EAE could be gained and in some cases treatments options for MS could be 
successfully evaluated, it needs to be highlighted that the results gained from EAE are not 
necessarily transferable to MS. Many therapies that showed success in EAE model were either 
inefficient or caused harmful side effects when used in MS patients. This discrepancy can result 
from the different genetic nature and temporal differences of immune reactivity and response to 
therapy between rodents and human. EAE displays more limitations: Compared to MS, EAE 
animals show less brain infiltrates and limited demyelination (Lovett-Racke, 2017). EAE mainly 
affects the spinal cord WM whereas in MS prominent demyelination of cerebral and cerebellar 
cortex is found. Since the basis for EAE is the injection of a self-peptide, the pathological 
changes found in EAE originate rather from a CD4+ cell activation. It was found that in MS the 
pathological changes are likely mainly CD8+ cell mediated, and B cell make an important 
contribution (Bettelli et al., 2003; Hauser et al., 2008). In many EAE models, however, the B cell 
contribution is missing which points out one of the deficiencies of EAE as an animal model for 
MS.   
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1.2 Mechanisms of axon degeneration 
 
As mentioned above, there are several mechanisms considered to be involved in axon 
degeneration in MS and EAE lesions. As already described FAD is a degenerative process 
characterized by focal swelling with subsequent fragmentation. It was also observed in axons 
with intact myelin sheaths in both EAE and acute MS lesions (Nikić et al., 2011). Wallerian 
degeneration, originally described in 1850, has been considered to be a prototypical axon 
degeneration process that mediates axonal demise not only after transection. Therefore, it has 
been proposed that some mechanism of Wallerian-like degeneration might be involved in 
axonal degeneration in EAE lesions as well. Other mediators, partly proposed as part of these 
degeneration cascades, e.g. high intra-axonal calcium levels, other molecules that are activated 
by increased calcium levels or ion channels are potential candidates as well. In the following 
sections, the possible molecular pathways of axonal loss will be discussed. 
 
1.2.1 Wallerian degeneration 
1.2.1.1 Introduction and pathogenesis 
 
It was long thought that the dying of axons is a passive process that results from deprivation of 
survival factors. About 170 years ago, August Waller observed that the peripheral axon distal 
from the transection injury degenerates, whereas the cell body remains intact (Waller, 1850). 
Such an anterograde degeneration is seen in neurodegenerative diseases as well, therefore 
this mechanism is known as “Wallerian-like degeneration” (WD). After a certain latent phase of 
around 24 - 48 hours the axonal cytoskeleton disintegrates, resulting in the breakdown of 
axonal membrane, disruption of myelin sheaths and attraction of macrophages. During this 
process axons exhibit focal swellings that are many times wider than a normal axon several 
hours before the actual fragmentation (Beirowski et al. 2010). These observations underline that 
WD is a sequential process (Simon et al., 1969). Following acute axonal degeneration (AAD) 
after a stab lesion the distal end begins rapidly to fragment after a heterogeneous latent phase 
(around 30 h) and spread in a proximal to distal direction, whereas the proximal axon bulb 
remained stable or even showed signs of early outgrowth (Kerschensteiner et al., 2005). 
Surprisingly, the distal ends of axons in C57BL/Wlds mice survive up to several weeks after 
nerve transection or crush in the PNS and CNS (Perry et al., 1991), suggesting that this kind of 
axonal dying back pathways are active processes.  
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1.2.1.2 Animal models with delayed Wallerian degeneration 
 
The discovery of Wallerian degeneration slow protein (Wlds) and its neuroprotective effect was a 
coincidence, but it ignited the quest for further insights into this retrograde degeneration 
mechanism. C57Bl/6 mice developed this mutation at a single locus spontaneous at Harlan 
Olac. WldS is a dose-dependent, semi-dominant phenotype that appears to be intrinsic to axons 
and does not interfere with other death pathways like apoptosis. Further research on molecular 
interactions involved in axonal degeneration delayed by WldS expression revealed that mice 
lacking Sarm1 exhibit a similar neuroprotective phenotype like WldS mice. On this way two 
popular rodent models to study the mechanisms of rapid Wallerian degeneration emerged: 
C57Bl/Wlds and Sarm1-/-. 
Further examination of the C57BL/Wlds revealed that compared to other lines these mice 
express an in-frame fusion protein that is a result of a spontaneous 85-kb tandem triplication 
within the distal chromosome 4 (Coleman et al., 1998). This chimeric gene is a fusion of the 5’ 
end of the ubiquitin conjugation factor E4 B (Ube4b) and the complete NMNAT1, a key enzyme 
involved in nicotinamide adenine dinucleotide (NAD+) biosynthesis (Mack et al., 2001). Mutating 
the nuclear localization sequence (ΔNLS) of Wlds retargeted the fusion protein from the nuclei to 
the cytosol that lead to a more robust protective effect of Wlds (Beirowski et al., 2009). 
Transgenic mice expressing Wlds or the stronger mutant ΔNLS-Wlds are widely used to examine 
neuron, axon or synapse protection in WD and in neurodegeneration models (Sajadi et al., 
2004; Wang et al., 2012; Wright et al., 2010).  
A F2 forward screen in Drosophila uncovered that loss of function of dSarm (Drosophila sterile 
alpha and Armadillo motif) provides axonal preservation that rivals that of Wlds in Drosophila. 
Endogenous dSarm therefore is required to drive WD in the nervous system and its discovery 
further supports the hypothesis that this degeneration pathway is an active program. Based on 
these results a transgenic mouse line with a null mutation for the mouse orthologue of dSarm, 
Sarm1 (or in mammals general known as MyD88-5) was created. After axotomy in vivo the 
synaptic integrity was preserved, and the cut distal axons remained intact several weeks after 
axotomy (rather than 2 days), indicating that the absence of Sarm1 protects as robustly as Wlds. 
Furthermore, these findings indicate that the axon destruction pathway is an ancient, 
evolutionary conserved mechanism (c.elegans, fruit fly, zebrafish, and mouse) (Osterloh et al., 
2012). A direct comparison of the protection capabilities in a non-injury, severe axonopathy 
model of NMNAT2 deficiency revealed that Sarm1 deletion rescues into old age, whereas mice 
rescued by Wlds/s developed hindlimb muscle denervation from 3 months and severe hindlimb 
paraparesis by 10 months (Gilley et al., 2017). This suggests that Sarm1 deficiency might be 
stronger protectant that WldS.  
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As Wlds and Sarm1-/- mice robustly protect against WD in injury models these transgenic mice 
are the model of choice to investigate the involvement of Wallerian-like mechanisms in 
neurodegeneration models, like EAE.  
 
1.2.1.3 Molecular pathways of Wallerian degeneration 
 
The exact molecular mechanisms of WD are still not fully understood and at times controversial. 
With the discovery of the Wlds, which exhibits Nmnat1 activity, the NAD+ scavenging pathway 
was identified as a potential key mechanism in WD. Furthermore, this is supported with 
expression of enzymatically dead versions of Wlds that fail to delay WD in flies (Avery et al., 
2009) or mice (Conforti et al., 2009). Expression of different modified constructs were used to 
dissect the function of different Wlds domains in Drosophila in vivo. This showed that 
relocalization of NMNAT enzymatic activity away from the nucleus showed maximal protection 
of severed axons. Interestingly, overexpression of Nmnat1 and Nmnat3, but not the nuclear 
Nmnat2, could mirror the neuroprotection of Wlds. Nmnat3 is known to be localized to 
mitochondria. This might indicate that the axon protection is exerted via Wlds/Nmnat activity in 
mitochondria (Avery et al., 2009). On the other hand, there is evidence that indicate that WD 
and NMNAT/Wldss-mediated axon protection is a mitochondria-independent mechanism (Kitay 
et al., 2013). In other words, the exact site of action of Wlds-sensitive protection remains elusive. 
It is as well not clear, if NAD+ is the protective Wlds product. Several studies interfering with 
NAD+ salvage pathway could not conclude that NAD+ is the sole key actor in Wlds protection 
(Conforti et al., 2009; Sasaki et al., 2009; Yahata et al., 2009). In summary, the mechanism of 
Wlds is more complex than simple overexpression of Nmnat1. The Ube4b domain of Wlds is 
certainly important for its function as well. Studies showed that an N-terminal 16 amino acid 
sequence of the chimeric protein binds to valosin-containing protein (VCP), thereby probably 
driving the relocalization of Wlds to sites outside of the nucleus. This is supported as well by the 
more potent Wlds mutant lacking the nuclear localization sequence: ΔNLS (Beirowski et al., 
2009).  
Since the chimeric gain of function Wlds protein is normally absent in wild-type organisms, the 
involvement of dSarm/Sarm1 in Wallerian-like degeneration (Osterloh et al., 2012) was an 
important finding towards understanding the endogenous axon destruction pathway, that is 
distinct from developmental axonal pruning and apoptotic cell death. Sarm1 belongs to the TIR 
domain containing family of proteins that act as scaffolding molecules downstream of Toll 
receptors in immune functions; but in contrast to the other family members, Sarm1 deletion 
does not impair TLR signaling (Kim et al., 2007). Additionally, Sarm1 contains SAM and 
Armadillo domains that mediate or modulate protein-protein interactions, respectively, that are 
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both important in initiation of Sarm1-mediated axon degeneration (Gerdts et al., 2013). Sarm1 is 
suggested to be activated by an injury-induced or dysfunction-induced Ca2+ signaling pathway 
(Rosenberg et al., 2012). The site of action of Sarm1 is still debated; antibodies developed 
against Sarm1 identified its localization to neurites (Chen et al., 2011) or mitochondria (Gerdts 
et al., 2013; Kim et al., 2007). For support of the latter, the Sarm1 sequence contains 
mitochondrial localization sequences (Panneerselvam et al., 2012). However, deletion of these 
has no positive effect on axon survival in vitro after axotomy (Gerdts et al., 2013).  
 
Although Sarm1 has no known enzymatic activity itself, its molecular structure indicates that 
Sarm1 probably forms multimers via SAM domain (Gerdts et al., 2013) and usually is auto-
inhibited probably via ARM in its N-terminal domain (Chuang and Bargmann, 2005). Upon 
injury, the conformation of Sarm1 might change, leading to exposure of the active TIR domains, 
which initiate the destructive pathway. Forced dimerization of the TIR domains is sufficient to 
Figure 2. Possible interaction of key players involved in Wallerian-like degeneration 
An injury of the axon leads to impaired anterograde transport that results in decrease of Nmnat2 
which catalyzes the production of NAD
+
. PHR1 activation leads to degradation of Nmnat2. [NAD
+
] loss can 
also be a result of TIR dimerization upon Sarm1 activation. Either way [NAD
+
] loss is associated with ATP 
depletion and energetic failure which finally results in axonal degeneration.  
Another consequence of Sarm1 activation is the activation of MAPK pathway and the consequent 
SCG10 loss which can be inhibited through Wld
S
. SCG10 regulates microtubule dynamic and is associated 
with axon regeneration. Presence of SCG10 interferes with Sarm1 dimerization and its loss leads to 
cytoskeletal breakdown. DLK/JNK are part of the MAPK pathway and have their role in promoting 
degeneration, e.g. JNK facilitates the SCG10 degradation. 
This overview scheme is a composition of (Gerdts et al., 2015), (Inman and Harun-Or-Rashid, 2017) 
and (Walker et al., 2017). 
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induce rapid axon fragmentation (Gerdts et al., 2013; Yang et al., 2015), by acting as an 
activating scaffold for further downstream effectors. The E3 ubiquitin ligase Highwire (Hiw) and 
its murine orthologue PAM/Highwire/Rpm1 (Phr1) are identified to be essential for WD, although 
their loss of function acts not as strong as Sarm1-/- (Babetto et al., 2013; Xiong et al., 2012). 
Figure 2 gives an overview of possible interactions that play a role in Wallerian-like 
degeneration.   
In summary, three key players have been identified for the execution of injury-induced axonal 
degeneration. First the pro-survival factor NMNAT2, whose depletion within the axon after injury 
is a trigger for WD. It is supposed that Wlds acts by regulating NMNAT2 levels within the axon. 
Dual leucine zipper kinases and associated MAP kinases are promoting axonal degradation and 
regeneration. Finally, Sarm1 plays the role as the central executioner.  
 
1.2.1.4 Wallerian degeneration-like pathways and MS 
 
Patterns of axonal loss that are consistent with classic Wallerian Degeneration were observed 
in MS patients from the early stages of the disease (Simon et al., 2000). It is assumed that 
Wallerian degeneration contributes significantly to axonal injury and loss in lesions (Dziedzic et 
al., 2010), but diffuse axonopathy was found in regions distant from the focal lesions, often 
independent of inflammatory demyelination (Haines et al., 2011).  
A few studies contribute further support to the hypothesis that Wallerian degeneration is at least 
partly contributing to the axonal loss seen in EAE lesions (Chitnis et al., 2007; Kaneko et al., 
2006). Mice expressing Wlds show an ameliorated disease course with modest protection 
against demyelination and neurodegeneration. Administration of Nicotinamide (NAm) improves 
axonal pathology and behavioral deficits, suggesting that Wlds and the NAD biosynthesis 
precursor nicotinamide (NAm) act through limiting the NAD decline that is seen in EAE lesions 
(Kaneko et al., 2006). Other studies, however, fail to reproduce the protective effect of WldS 
expression in EAE (Singh et al., 2017). Since neurodegeneration in EAE and MS lesions has no 
clear onset, the neuronal damage observed is a combination of acute degenerative damage 
that might be WldS-insensitive and secondary degeneration that resembles classical WD.  
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1.2.2 Excitotoxic neurodegeneration 
 
Another suggested mechanism how neurons and their axons undergo death is excitotoxicity 
due to uncontrolled glutamate release-induced persistent depolarization and calcium influx. This 
kind of cell death program is called accidental necrosis due to the absence of death receptor 
signaling. Glutamate is the primary excitatory neurotransmitter in the peripheral and central 
nervous system and it is involved in several essential activities, like cognition, learning, memory, 
but also it contributes to the development of the CNS. Glutamate modulates the connection of 
the CNS with peripheral organs and therefore contributes to cardiorespiratory, endocrine and 
reproductive functions. Since glutamate affects so many vital functions but is also a basic amino 
acid and nutrition factor, it is essential that glutamate signaling is tightly controlled, especially in 
the CNS. Oxidative stress, Ca2+ overload, mitochondrial dysfunction and energy deficiency can 
lead rapidly to abnormalities of excess glutamate (Levite, 2017). MS patients were found to 
have a disturbed glutamate homeostasis. Either their glutamate levels in the CSF (Sarchielli et 
al., 2003) or brain (Cianfoni et al., 2007) are elevated, or the expression of actors of the 
glutamate homeostasis like glutaminase and glutamate transporters are found to be highly 
expressed in active MS lesions (Werner et al., 2001). Furthermore, there is evidence that 
glutamate activates its receptors in autoimmune T cells that lead to cytotoxicity and 
neuroinflammation. Glutamate-activated T cells produce more glutamate that contributes further 
to the excitotoxicity and further autoimmunity (Levite, 2017). Other immune and glial cells are 
also known to have the capabilities to expel and take up the neurotransmitter. 
The uncontrolled release of glutamate leads to overactivation of glutamatergic receptors. The 
resulting persistent depolarization damages the neuron. The duration of depolarization should 
usually be self-limited and end with the depletion of glutamate vesicles. However, the neuron 
remains in a depolarized state long after the initial injury, finally leading to the neuron’s death. 
This suggest that excitotoxicity has two parts: a glutamate-dependent and a glutamate-
independent step.  
 
1.2.2.1 Molecular pathways of axon fragmentation 
 
There is increasing evidence that the transient receptor potential M4 (TrpM4) channel is 
involved in the glutamate-independent step of excitotoxicity. TrpM4 is a non-selective cation 
channel of the TRP superfamily, permeable to monovalent cations, especially sodium and 
potassium that is activated by intracellular Ca2+ and low ATP concentration (Guo et al., 2017). 
Overactivation of TrpM4 might be a possible explanation for the depolarization despite 
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glutamate depletion (Simard and Gerzanich, 2017). By pharmacologically blocking or silencing 
TrpM4, the depolarization could be reduced in a cerebral ischemia-reperfusion model (Leiva-
Salcedo et al., 2017). More evidence for the involvement of TrpM4 is the nature of the channel 
itself. Under physiological conditions TrpM4 is blocked by intracellular ATP. The necessary ATP 
concentration of the TrpM4 blockage is very low (Ullrich et al., 2005). Such low ATP 
concentration is usually associated with a severe metabolic depletion bordering on cell death. If 
the challenging condition persist, this can lead to an unchecked channel opening, Na+ overload 
leading to membrane disruption and even rupture (Simard et al., 2012). Schattling et al. could 
show that the lack of Trpm4 saves neurons from glutamate-induced depolarization and cell 
body swelling (Schattling et al., 2012).  
 
Figure 3. Molecular mechanism of axonal swelling induced by activated TrpM4 
Glutamate Receptors GluR are activated by excess extracellular glutamate (Glu) which results in a channel 
opening and a rise in intraaxonal calcium (Ca) and sodium (Na). Increased intraaxonal Calcium and ATP 
depletion activate TrpM4 channel that potentiate sodium influx which is associated with oncotic axonal 
swelling and subsequent degeneration. Figure inspired by Friese et al. 2014. 
 
TrpM4 is ubiquitously expressed in different cell types. Its exact physiological role is still 
unclear. It was found that TrpM4 is de novo expressed in capillaries after traumatic impact, 
thereby initiating secondary hemorrhage (Gerzanich et al., 2009). Isolated cardiac conduction 
disease is linked to a gain-of-function mutation in the TRPM4 gene (Liu et al., 2010). 
Physiologically, TrpM4 is likely associated with regulation of Ca2+ oscillations and therefore 
influences Ca2+ signaling in different cells (Launay et al., 2004). For instance, TrpM4 expression 
is identified to drive NFATc1 localization in T cells to the nucleus (Weber et al., 2010), where it 
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has a different effect on various T cell subsets. The inhibition of TrpM4 expression in Th1 cells 
lead to a decrease in Ca2+ levels and nuclear NFATc1, resulting in less motile Th1 cells with 
increased cytokine expression. In Th2 cells inhibition of TrpM4 expression had an opposite 
effect. Figure 3 shows an overview of the molecular mechanisms that are possibly involved in 
TrpM4-dependent axonal swelling. 
Taken all together, TrpM4 is a good candidate for a common converging downstream 
mechanisms of neuronal cell death as response to energy failure and Ca2+ influx, which are 
seen in several neurodegenerative diseases like in MS, Alzheimer’s disease and stroke.  
 
1.2.2.2 Involvement of TrpM4 in MS 
 
TrpM4 is expressed in motor neurons of human spinal cord and cerebral cortex. In active 
demyelinating MS lesions, the proportion of TrpM4 expressing axons is significantly higher 
compared to healthy individuals (Schattling et al., 2012). This increase in immunoreactivity is 
only seen in active demyelinating lesions, whereas in inactive lesions or non-inflamed 
periplaque white matter only a small proportion of TrpM4+ axons was detected. These findings 
could be reproduced in EAE mice (Schattling et al., 2012). Although, it was discovered that 
TrpM4 modulates immune cell function, the deletion of TrpM4 in mice was not modifying the 
EAE autoimmune responses (Schattling et al., 2012). Nevertheless, mice deficient in TrpM4 
showed reduced disease severity compared to WT littermates (Schattling et al., 2012). With the 
inhibition of TrpM4 currents via glibenclamide in WT mice this amelioration could be 
reproduced. Glibenclamide does not only block TrpM4 currents, it is rather associated to inhibit 
sulfonylurea receptor 1 (Sur1). TrpM4 and Sur1 were found to form de novo heterodimeric 
channels upon CNS injury (Tosun et al., 2013; Woo et al., 2013) and Sur1-TrpM4 is upregulated 
in astrocytes in EAE lesions (Makar et al., 2015). Inflammatory burden, demyelination, axonal 
damage and the overall clinical disease scores are reduced in mice deficient in Abcc8, which 
encodes for the Sur1 channel (Makar et al., 2015). A recent study further supported that 
inhibition of Sur1-TrpM4 via glibenclamide is beneficial during the chronic phase of EAE. 
Moreover, they found that Sur1 is upregulated in demyelinating, active lesions of MS patients 
(Gerzanich et al., 2017). 
Global gene silencing of either Trpm4 or Abcc8 (encoding for Sur1) are found to exert similar 
beneficial effects on inflammation, myelin preservation and neurological function. Therefore, 
TrpM4 might be a potential target to ameliorate EAE progression. 
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1.2.3 Calpains 
1.2.3.1 Molecular pathways (Calpain-Calpastatin system) 
 
The calpain system consists of calpain and its endogenous highly specific inhibitor calpastatin. 
Calpain is a Ca2+-dependent cysteine protease with papain-like activity that is activated upon 
increased Ca2+ concentration. There are two isoforms of calpain that differ in Ca2+ sensitivity 
(Cong et al., 1989). μ-calpain or calpain I is located in the cytosol or near the membrane and 
senses small changes in the Ca2+ concentrations. Physiological Ca2+ concentration ranges from 
100 – 1000 nM, whereas under excitotoxic condition it can rise up to 5 – 10 μM (Campbell, 
2014). On the other hand, m-calpain or calpain II is found at the membrane and requires mM 
concentrations of Ca2+ for activation. It is more likely that m-calpain is activated through an 
intracellular signaling pathway that involves its phosphorylation by PKA (protein kinase A) (Goll 
et al., 2003) or translocation to plasma membrane (Leloup et al., 2010). Both calpains 
autoproteolyze in the presence of Ca2+, thereby reducing the Ca2+ concentration required for 
half-maximal proteolytic activity without affecting the specific activity (Goll et al., 2003). 
Figure 4. Calpain-Calpastatin-System 
Under physiological conditions it is proposed that procalpain translocates to the membrane or binds 
to an activator molecule, in both ways activating calpain that then, in turn, regulates cell processes through 
specific proteolysis. For activation the procalpain molecule proteolyzes itself. In injury or disease, the 
intracelluar calcicum rises to pathological levels, which leads to an uncontrolled activation of calpain and an 
extensive proteolysis. There are several control mechanisms: calpastatin interacts in an inhibitory way with 
calpain under increase of intracellular calcium. Furthermore, calpain has a build-in self-regulation: further 
autolysis leads to deactivation of calpain. It was reported that caspase-3 and activated calpain can degrade 
calpastatin. The calpastatin fragments can enhance the calpain activity.  
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Calpastatin is an endogenous inhibitor that specifically inhibits calpain and no other protease 
(Cottin et al., 1981). It derives from one single gene and exists in different splicing variants 
depending on tissue localization and physiological states (Goll et al., 2003; Tullio et al., 2007). 
The physiological significance of these different variants remains still a mystery. It is required 
that Ca2+ binds to calpain for inhibitory interaction with calpastatin (Otsuka and Goll, 1987). The 
necessary concentration for binding is dependent on the calpain isoform and inhibition can be 
reversed via chelating calcium with EDTA. Immunolocalization reveals that calpain and 
calpastatin are frequently colocalized in the cell. Based on the required calcium concentrations 
in vitro calpain is rather found to be bound to calpastatin before its proteolytic activity is initiated. 
This is supported by the frequent colocalization of calpain and its specific inhibitor in the cell 
(Goll et al., 2003). There are a few proposed mechanisms that allow calpain activity in the cell 
despite calpastatin presence. Either the required calcium concentration for proteolytic activity is 
decreased in certain conditions (Goll et al., 1992) or calpain is separated through translocation 
away from calpastatin to be able to act (Goll et al., 2003). 
Calpains recognize only a limited number of cleavage sites and the cleavage leads mostly to 
large, catalytically active fragments. This and the nature of the substrates indicates that calpains 
have rather a regulatory and signaling function than solely a digestive function. It is involved in 
cell motility by cleaving cytoskeleton substrates like cadherin, myosin, neurofilament and alpha-
II-spectrin. Calpain substrates are e.g. kinases and phosphatases like PKC that modulate gene 
expression, signal transduction and long-term potentiation (Goll et al., 2003; Liu et al., 2008). 
Knockout mice lines have shown calpain is essential for embryonal development (Zimmerman 
et al., 2000). The role of calpain in apoptosis is not clear. There is evidence that calpain inhibits 
apoptosis by inactivating upstream caspases, but as well that calpain acts as positive regulator 
of apoptosis, being aligned with the direct degradation of cytoskeletal proteins by calpain 
(Momeni, 2011; Squier et al., 1994). However, calpain was found to play a role as well in other 
cell death mechanisms as necroptosis, autophagy and others (Orrenius et al., 2015). 
Figure 2 illustrates a summary of the complex calpain-calpastatin-system. Under physiological 
cytosolic calcium concentration, the proenzyme procalpain gets activated by translocalization to 
the plasma membrane where it interacts with PIP2 (Leloup et al., 2010) or by binding of 
activator molecules (Pontremoli et al., 1990). In this way calpain can act modulatory by specific 
proteolysis of limited substrates. The activation of calpain is controlled by binding of calpastatin 
to calpain. If the cytosolic calcium levels increase extensively, calpain gets activated and 
proteolyzes in an uncontrolled manner that results in i.a. cytoskeletal breakdown. The latter is 
proposed to be involved in neurodegeneration.  
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1.2.3.2 Calpain involvement in MS and MS models 
 
Under physiological conditions only a few calpain molecules are activated in a controlled way, 
allowing reorganization of the cellular scaffold - in process of synapses remodeling and memory 
formation (Liu et al., 2008). However, sustained increase in calcium concentration, as it is found 
in pathological conditions, activates all calpains present in the cell. In traumatic brain injury, the 
calcium rises with severe cellular damage, thereby initiating calpain mediated neuronal death 
and axonal disintegration (Schoch et al., 2012; Huh et al., 2006). Indeed, viral overexpression of 
calpastatin restored the deficits in axonal transport after optic nerve stretch injury (Ma et al., 
2012). Likewise, inhibiting calpain in a spinal cord contusion injury saved the axons from 
fragmentation (Williams et al., 2014). 
Since myelin proteins are substrates of activated calpain (Sloane et al., 2003), it seems likely 
that calpain also plays a role in myelin degradation. In spinal cords of Lewis rats with EAE the 
transcriptional expression of the calpain system was not altered. On translational level, 
however, expression of calpain was highly increased in combination with myelin loss. A 
correlative study in Lewis rats showed that increased calpain activity correlates with clinical 
symptoms and cell infiltration (Schaecher et al., 2002). In PBMC cells from MS patients calpain 
activity is increased as well. Treatment with calpeptin decreased the Th1 cytokines and myelin 
degradation (Imam et al., 2007). During relapses, infiltrating immune cell are suggested to 
secrete calpain that initiates myelin breakdown. Further, calpain overactivation has been 
implicated in neurodegeneration in MS and EAE lesions (Das et al., 2008). With double-
immunofluorescence labeling an overexpression of m-calpain was found to be localized to 
NeuN positive cells. Axonal damage was not evident until the onset of clinical symptoms and it 
correlated with increased calpain expression. However, neuronal death occurs later in the 
course of disease (Das et al., 2008; Guyton et al., 2005). Axonal injury can be prevented in 
acute and chronic EAE using calpain inhibitors, reducing inflammation, demyelination as well as 
markers of axonal injury like APP (Hassen et al., 2006; 2008).  
Taken all together, calpain is another promising candidate mediator of axonal degeneration in 
MS and EAE. It is activated in presence of high intracellular calcium levels and cytoskeletal 
proteins Iike spectrin are among its various substrates.  
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1.3 In vivo visualization of neuronal calcium levels 
1.3.1 Principles of 2-photon excitation microscopy 
 
The biggest challenge in high-resolution imaging of biological tissue is the limitation of light 
scattering that results in blurred, suboptimal resolution. Due to scattering, emitted photons 
cannot be addressed to their origin. Therefore, the tissue penetration in conventional (linear) 
one photon microscopy is limited to less than 100 µm (near the tissue surface).  
In the last decades, non-linear microscopy was developed that reduced the limitations of 
surface and tissue light scattering. 1990 Denk combined the principle of laser scanner 
microscopy with the principle of 2-photon excitation, which is a higher order light-matter 
interaction and is therefore not linearly dependent on the incident light intensity.  
In fluorescence microscopy a single electron of the fluorophore is usually excited by a photon, 
whose energy matches the energy difference between the electronic ground state S0 and 
excited state S1. The relaxation and falling back to S0 results in an emission of a photon from 
the excited fluorophore. The wavelength of the emitted photon depends on the energy 
difference between the excited and ground state (see Figure 5). 
This excitation can be achieved as well by 2 photons in the near-infrared wavelength range that 
simultaneously (within 0.5 fs) arrive at the molecule (see Figure 5). The generated emission 
photons have higher energies than the excitation light, the emission occurs in the visible 
spectral range. To achieve a higher excitation efficiency, the incident light source needs to be 
highly concentrated in photons in time (short pulse laser) and space (higher N.A. for high spatial 
intensities). As the laser beam is focused, the probability of two photons interacting 
simultaneously with a single fluorophore is increased. These properties explain the difference in 
excitation volume:  
In case of single photon microscopy, the excitation is not limited to a focal point. Fluorophores 
can be stimulated above and below the focal plane. Confocal microscopy achieves a better z-
resolution and optical sectioning via introducing a pinhole in the detection light pathway that 
excludes light that does not originate from the focal plane. This detection pinhole filters the 
depth of focus and blocks signals not originating from the focal plane. Although the pinhole 
enhances Z-resolution, absorption outside the focal plane is not inhibited. This can lead to 
photobleaching and phototoxicity in the cone-shape excitation volume. Furthermore, the 
insertion of the pinhole reduces the intensity of the detected signal and therefore the signal-to 
noise ratio.  
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Figure 5. Overview of confocal and 2 photon principles.  
(A) Jablonski diagram illustrating one and two-photon excitation of a fluorophore from the ground state S0 to 
the excited state S1. (B) In the case of single-photon microscopy laser light with lower wavelength is used 
and the excitation results in a cone-shaped excitation volume. For 2-photon microscopy near infra-red light 
is used for excitation and there is no out-of-focus signal. Inspired by, Helmchen and Denk, 2005. 
 
For 2-photon excitation, on the other hand, the high spatial and temporal photon density needed 
is only reached in the focus point of the excitation laser. Above and below this focus point the 
photon density is not sufficient. This provides an inherent three-dimensional resolution without 
the usage of a pinhole that reduces signal intensity (see Figure 5, lower part). Additionally, 
photobleaching and phototoxicity occur only in close proximity to the focal point (Denk et al., 
1990). However, the usage of highly dense photons in near-infrared spectrum for excitation can 
harm the tissue by photothermal damage or optical breakdown (Hopt and Neher, 2001; König, 
2006).  
In summary, 2-photon excitation microscopy is a strong tool for in vivo imaging. It provides the 
same optical sectioning capability combined with a better tissue penetration (up to 800 µm), 
stronger in-focus signal with minimal photobleaching and phototoxic effects. 
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1.3.2 Genetically encoded calcium indicators 
 
As Ca2+ is a universal secondary messenger and is involved in many essential regulatory and 
signaling pathways, the need of developing an appropriate indicator for studying the 
involvement of Ca2+ is high. In mammalian neurons the intracellular calcium concentration is 
around 50 – 100 nM and can increase transiently during electrical activity up to levels 100 times 
higher.  This broad concentration range and the mode of dye delivery are challenges for calcium 
sensor design. Furthermore, the commonly used delivery approaches like bulk or intracellular 
loadings of synthetic Ca2+ sensors are not cell type or population specific. Since the invasive 
application of these indicators causes tissue damage, they are not suitable for chronic repetitive 
in vivo imaging.  
Genetically encoded Ca2+ indicators (GECI) are more suitable for in vivo imaging. Their delivery 
is minimal invasive and since they are expressed robustly a stable baseline can be measured. 
Ideally, GECI show a decent signal for Ca2+ transients without interfering with intracellular 
processes and ion homeostasis. For quantitative imaging, a sensor is needed that changes its 
emission and/or excitation behavior according to the Ca2+ concentration. Miyawaki and 
colleagues designed the first version of a FRET based GECI that is composed of two 
fluorophores connected by a peptide that induces conformational changes upon Ca2+ binding 
(Miyawaki et al., 1997). The two fluorophores are chosen in such a manner that Förster 
resonance energy transfer (FRET) can occur. The emission spectrum of one fluorophore, the 
donor, overlaps partially with the excitation spectrum of the higher wavelength fluorophore, the 
acceptor. If donor and acceptor are less than 100 Å apart a non-radiative energy transfer occurs 
if the donor is excited (Jares-Erijman and Jovin, 2003). Over the last years GECI were 
optimized with brighter fluorophore variants and different Ca2+ binding domains that have an 
influence on the Ca2+ binding affinity and kinetics (Rose et al., 2014). 
By injecting purified linear DNA fragments of the engineered sensor into pronuclei of mouse 
oocytes, transgenic mouse lines were produced that stably express the GECI variant CerTNL15 
under the Thy1 promotor that drives expression in neurons (Heim et al., 2007). CerTNL15 is 
composed of the fluorophore duo Cerulean and YFP and a chicken variant of the skeletal 
muscle Troponin C which shows improved Ca2+ sensitivity and sensor brightness compared to 
previous biosensor variants. This transgenic mouse line allows the investigation of Ca2+ levels in 
distinct neurons and their dendrites in the healthy and the diseased nervous system.  
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1.3.3 Intra-vital 2-Photon microscopy of the healthy and diseased nervous 
system 
 
In vivo imaging has been a powerful analytical approach to resolve cell biological processes in 
healthy and diseased context, including axonal degeneration and regeneration. With 
conventional in vitro methods, immunohistochemistry or postmortem analysis a clear 
discrimination of different degeneration mechanisms is difficult. Only limited conclusions can be 
drawn from in vitro studies about the mechanisms in the intact organism. Before introduction of 
2-photon excitation microscopy, imaging in tissue was challenging. Wide-field and confocal 
microscopy usually have compromised resolution and a low signal-to-noise ratio due to higher 
light scattering. 2-photon excitation microscopy allows the visualization of dynamics and time 
resolution of processes in their natural physiological environment in living animals. Although 
mechanisms are preferably first studied in a simplified manner that is easier to manipulate, like 
cell culture and ex vivo brain slice culture, it is difficult to recreate axons and their exact native 
context. 2-photon excitation microscopy and development of various calcium sensors enabled 
the investigation of the mammalian CNS in vivo (Helmchen and Waters, 2002). The spine 
dynamics in a healthy rodent brain can be observed and manipulated, thereby increasing our 
understanding of long-term potentiation and memory formation. With the in vivo approach, 
axonal disintegration in EAE lesions could be observed in vivo. Furthermore, it could be shown 
that this axonal degeneration is in some degree reversible, thereby revealing a therapeutic 
potential for intervention (Nikić et al., 2011). Utilizing intra-vital dyes it is possible to investigate 
other cellular signaling molecule in neurons or other cells and organelles within a cell 
(Romanelli et al., 2013). In the past years other genetically encoded biosensors were developed 
that detect changes in membrane potential (Storace et al., 2015), mitochondrial redox signals 
(Breckwoldt et al., 2014) or NADPH metabolism (Tao et al., 2017). The microtubule dynamics 
within different neuronal compartments could be visualized using a transgenic mouse line that 
expresses EB3 fused to yellow fluorescent protein (YFP) (Kleele et al., 2014). With the 
development of another transgenic mouse line that labeled all neuronal mitochondria with a 
fluorophore (Thy1-mitoCFP and nse-mitoYFP) in vivo imaging of mitochondrial transport and its 
changes in pathology in vivo was possible (Misgeld et al., 2007; Sorbara et al., 2014). 
Thus, a diverse biosensor toolset emerged over the years that allows together with the 
constantly improving in vivo imaging techniques to get better insights in the complex 
pathogenesis of nervous system disease including the mechanisms that mediate the 
degeneration of axons in inflammatory lesions. 
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2 Objectives 
Previous work in our lab could identify that axons in acute EAE lesions undergo focal axonal 
degeneration which is an active sequential process that still has potential to recover in the early 
phases (Nikić et al., 2011). Using a transgenic mouse line that expresses a FRET based 
calcium sensor in neurons our group could further show that intra-axonal calcium levels can 
predict the probability of axons to degenerate within an acute EAE lesion. The overall aim of my 
PhD project was to investigate how this axonal degeneration is initiated through pathologically 
increased intra-axonal calcium concentrations in EAE lesions. 
There are several molecular candidates that are known to be involved in axonal degeneration in 
other contexts. In particular, I focused my investigation on three candidate mechanisms that 
might be triggered in acute EAE lesions: Wallerian-like degeneration, TrpM4 induced axonal 
damage and calpain-initiated axonal fragmentation. This work aims to answer the following 
specific questions: 
 Do genetic mutations that inhibit Wallerian-like degeneration such as Sarm1 loss or the 
presence of the fusion protein WldS affect Ca2+-mediated inflammatory axon 
degeneration in vivo and do they have any effect on the lesion pathology or axonal 
morphology within acute or chronic EAE lesions? 
 Does lack of TrpM4 alter the intra-axonal calcium concentration and degeneration 
sequence in vivo within acute EAE lesions? 
 Can pharmacological inhibition of calpain in vivo change the fate of axons with increased 
calcium levels and can a long-term treatment influence the disease outcome?  
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3 Materials and Methods 
3.1 Material list 
3.1.1 Surgery procedures 
3.1.1.1 Surgery reagents 
 
Description Source 
Ketamine hydrochloride 10% (Ketamine)  Bremer Pharma GmbH, Warburg, Germany  
Xylariem 20 mg (Xylazine)  Riemser Arzneimittel AG, Greifswald-Insel 
Riems, Germany  
Forene (Isoflurane)  Abbott AG, Baar, Switzerland  
Sterile artificial mouse cerebrospinal fluid 
(aCSF)  
Solution A:  
8,66 g NaCl (Merck)  
0,224 g KCl (Merck)  
0,206 g CaCl2 · 2H2O (Sigma-Aldrich)  
0,163 g MgCl2 · 6H2O (Sigma-Aldrich)  
 
Solution B:  
0,214 g Na2HPO4 · 7H2O (Merck)  
0,027 g NaH2PO4 · H2O (Merck)  
dH20 ad 500 ml  
Mixture of solutions A and B in a 1:1 ratio  
Bepanthen Augen- und Nasensalbe 5 g 
(eye ointment)  
Bayer Vital GmbH, Leverkusen, Germany  
Ringerlösung Fresenius KabiPac  
(Ringer’s solution)  
Fresenius KaBI Dtl., Bad Homburg, Deutschland  
Cutasept F Lösung 250 ml  
(disinfectant spray)  
Bode Chemie GmbH & Co, Hamburg, Germany  
Agarose  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany  
Ethanol 70 % CLN GmbH, 85416 Niederhummel, Germany 
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3.1.1.2 Surgical tools and materials 
Description Source 
Wella contura W7807 (Hair clipper)  Wella, Darmstadt, Germany  
Syringe 3pc 5 ml OmnifixTM luer slip 
(syringe for injection of Ringer’s solution)  
B. Braun Melsungen AG, Melsungen, Germany  
BD Plastipak Hypodermic luer slip syringe 
1 ml (syringe for Ketamine/Xylazine and 
Ptx injection)  
Becton, Dickinson and Company, Franklin 
Lakes (New Jersey), USA  
Feather stainless steel blade (surgical 
blade)  
pfm medical ag, Cologne, Germany  
Noyes Spring Scissors (Large spring 
scissors)  
Fine Science Tools GmbH, Heidelberg, 
Germany  
Vannas-Tübingen Spring Scissors  
(Small angled spring scissors)  
Fine Science Tools GmbH, Heidelberg, 
Germany  
Dumont Mini Forceps – Inox Style 3 (Small 
forceps)  
Fine Science Tools GmbH, Heidelberg, 
Germany  
Dumont Mini Forceps – Inox Style 5 (Small 
forceps, smaller tip than Inox style 3)  
Fine Science Tools GmbH, Heidelberg, 
Germany  
Hypodermic Needles BD Microlance 3 30 
Gauge (0,3 mm, yellow) for subcutaneous 
injection of Ringer’s solution and 
anesthesia  
Becton, Dickinson and Company, Franklin 
Lakes  
(New Jersey), USA  
Ethicon Ethilon monofil 6-0 size,  
667H (skin suture)  
Johnson & Johnson Medical GmbH, 
Norderstedt,  
Germany  
Ethicon Vicryl 4-0 size, MIC101H  
(intracorporal suture)  
Johnson & Johnson Medical GmbH, 
Norderstedt,  
Germany  
Sugi (absorbent triangles)  Kettenbach GmbH & Co. KG, Eschenburg, 
Germany  
Metal plate  Custom-made  
Cast Alnico Button Magnets  Eclipse Magnetics Ltd, Sheffield, UK  
Rubber band  
Support cushion  Custom-made  
Osmotic minipump (Model 1007B) Alzet, Cupertino (California), USA 
Intrathecal catheter (Model 7743) Alzet, Cupertino (California), USA 
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3.1.1.3 Devices 
 
Description Source 
Olympus KL 1500 LCD (cold light source 
for stereomicroscopy)  
Olympus Deutschland GmbH, Hamburg, Germany  
Olympus Stereo Microscope SZ51  Olympus Deutschland GmbH, Hamburg, Germany  
FST 250 Hot Bead Sterilizer (sterilizer for 
surgical instruments)  
Fine Science Tools GmbH, Heidelberg, Germany  
T/Pump (Heating pad)  Gaymar Industries, Orchard Park (New York), 
USA  
MouseOx Plus® Rat & Mouse Pulse 
Oximeter 
Starr Life Sciences Corp., 333 Allegheny Ave, 
Oakmont, PA 15139, United States 
Mouse Thigh Sensor Starr Life Sciences Corp., 333 Allegheny Ave, 
Oakmont, PA 15139, United States 
Mouse Temperature Sensor Starr Life Sciences Corp., 333 Allegheny Ave, 
Oakmont, PA 15139, United States 
 
3.1.2 Perfusion and immunohistochemistry 
3.1.2.1 Reagents 
 
Description Source 
PFA (paraformaldehyde) 4%  8% PFA (Sigma-Aldrich) in dH2O, heated up to 55 °C and stirred additional 10 min,  
filtrated and mixed in a 1:1 ratio with 0.2 M  
PB (Phosphate buffer), pH adjusted to 7.2-7.8  
Triton X-100  Sigma-Aldrich, Chemie GmbH, 82024 Taufkirchen, Germany  
30 % Sucrose  Sigma-Aldrich, Chemie GmbH, 82024 Taufkirchen, Germany  
Phosphate Buffered Saline (PBS) 10x, 
pH=7,2/7,4  
2,6 g NaH2PO4 · H2O  
14,4g Na2 HPO4· 2H2O  
87,5g NaCl (Merck)  
dH2O ad 1l  
TBS 10x (Tris buffered saline), pH=7,6  61 g Tris base (121,14 g/mol), (Sigma-  
Aldrich)  
90 g NaCl  
dH2O ad 1l  
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Phosphate Buffer (PB) O,2 M 27,598 g NaH2PO4· H2O,  
35,598 g Na2 HPO4· 2H2O  
dH2O ad 1l  
Gibco goat serum  Invitrogen GmbH, Darmstadt, Germany  
DMSO  Sigma-Aldrich® Chemie GmbH, 82024 Taufkirchen, Germany  
Cryoprotective Solution: 25 % Glycerol 
(85%), 25 % Etyhlenglycol, 50 % PBSx1 
Custom made 
Chemicals from Sigma-Aldrich® Chemie GmbH, 82024 Taufkirchen, Germany 
0.1 % Sodium Azide (NaN3) in PBSx1 Sigma-Aldrich, Chemie GmbH, 82024 Taufkirchen, Germany 
Sodium Citrate Buffer 10mM Sodium Citrate, pH 8.5 
 
3.1.2.2 Antibodies, vital dyes and tracers 
 
Antibody Source 
Polyclonal rabbit anti-Iba1  SynapticSystems #234013  
Polyclonal rat anti-CD3 Serotec, MCA1477 
Polyclonal anit-HA  GeneTex, #GTX115044 
Rabbit anti-spectrin Millipore 
Goat-anti-rabbit Alexa fluor® 594 antibody  Invitrogen GmbH, Darmstadt, Germany  
Goat-anti-mouse Alexa fluor® 635 antibody  Invitrogen GmbH, Darmstadt, Germany  
Goat-anti-rabbit Alexa fluor® 488 antibody  Invitrogen GmbH, Darmstadt, Germany  
Neurotrace 435/455 blue fluorescent Nissl 
stain  
Invitrogen GmbH, Darmstadt, Germany  
Neurotrace 640/660  
deep-red fluorescent Nissl stain  
Invitrogen GmbH, Darmstadt, Germany  
Goat-anti-rat Alexa fluor® 594 antibody Invitrogen GmbH, Darmstadt, Germany  
Goat-anti-rat Alexa fluor® 635 antibody Invitrogen GmbH, Darmstadt, Germany  
 
  
Materials and Methods 
 
 
33 
 
3.1.2.3 Tools and materials for histology 
 
Description Source 
Microscope slides 76x26 mm  Gerhard Menzel Glasbearbeitungswerk  
GmbH & Co. KG, Braunschweig, Germany  
Microscope cover slips 24x60 mm  Gerhard Menzel Glasbearbeitungswerk  
GmbH & Co. KG, Braunschweig, Germany  
Parafilm  Brand GmbH & Co. KG, Wertheim  
Germany  
Pipettes, pipette tips and tubes (2ml and 
1,5  
ml)  
Eppendorf AG, Hamburg, Germany  
12-well cell culture plates  Becton, Dickinson and Company, Franklin  
Lakes (New Jersey), USA  
Tissue Tek Cryomold Standard, 25x20x5 
mm  
Sakura Finetek Europe B.V., Alphen aan den 
Rijn, The Netherlands  
Tissue Tek Cryomold Biopsy, 10x10x5 
mm  
Sakura Finetek Europe B.V., Alphen aan den 
Rijn, The Netherlands  
Tissue Tek optimal cutting temperature  
(O.C.T.)  
Sakura Finetek Europe B.V., Alphen aan den 
Rijn, The Netherlands  
Vectashield Mounting Medium  Vector Laboratories, Inc., Burlingame  
(California), USA  
Paper filters (185 mm Ø circles)  Whatman Schleicher & Schuell GmbH,  
Dassel, Germany  
50 ml centrifuge tubes  Greiner Bio-One GmbH, Frickenhausen,  
Germany  
 
3.1.2.4 Technical devices 
 
Description Source 
Leica CM1850 cryostat  Leica Microsystems GmbH, Wetzlar, Germany 
Vibratome 1000Plus  Intracel LTD, Shepreth, Royston, Great Britain 
Vortex-Genie 2 Scientific Industries, Inc., Bohemia (New York), 
USA 
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KERN EW 150-3M (scales)  Kern & Sohn GmbH, Balingen-Frommern, 
Germany  
Laboratory pH meter inoLAB WTW Wissenschaftlich-Technische 
Werkstätten, Weilheim, Germany  
Magnetic stirring hotplate MR 3001K  
and stirring bars  
Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany  
Ismatec IP high precision multichannel 
pump (pump for perfusions) 
ISMATEC SA, Labortechnik – Analytik, 
Glattbrugg, Switzerland 
Olympus IX71inverted fluorescence 
microscope 
Olympus GmbH, Hamburg, Germany 
 
3.1.3 Imaging 
3.1.3.1 Imaging devices 
 
Description Source 
FV1000 confocal system mounted on an  
upright BX61 microscope, equipped with an 
y10/0.4 water immersion objective and x20/0.85 
and x60/1.42 oil immersion objectives (confocal 
microscopy) 
Olympus GmbH, Hamburg, Germany  
Olympus FV1000 MPE multiphoton  
Microscope 
X25/1,05 water immersion objective  
Olympus GmbH, Hamburg, Germany  
Objectives: x4/0.13, x10/0.4 air objectives; 
x25/1.05 water immersion objective; x40/0.85, 
x60/1.42 oil immersion objectives  
Olympus GmbH, Hamburg, Germany  
Small animal ventilator  Harvard Apparatus  
Intratracheal cannula (1.0 mm OD, 13 mm length)  Harvard Apparatus  
Spinal clamping device (spinal adaptor for a 
stereotaxic frama)  
Narishige STS-A  
Gravity superfusion system containing in-line 
heater  
Warner Instruments  
vacuum system with suction tube  Custom-built  
Stage for spinal clamping device  Luigs & Neumann SM 5-9 stage and 
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controller unit  
MaiTai eHP/HP titanium:sapphire laser Newport/Spectraphysics, Irvine, 
California, USA 
 
3.1.4 EAE induction 
3.1.4.1 Reagents for immunization 
 
Description Source 
Purified recombinant MOG (from E. Coli)  Stock solution, produced by laboratory of Doron 
Merkler (Universität Göttingen, University of 
Geneva) and by laboratory of Martin 
Kerschensteiner 
Purified MOG peptide (N35-55)  Schafer-N Copenhagen, Denmark  
Mycobacterium Tuberculosis H37 RA  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany  
Incomplete Freund’s adjuvant (IFA)  Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany  
Pertussis toxin from Bordetella pertussis, 
inactivated  
Sigma-Aldrich® Chemie GmbH, 82024 
Taufkirchen, Germany  
 
3.1.4.2 Tools for immunization 
 
Description Source 
10 ml syringes  Hamilton  
Hypodermic Needles BD Microlance  
3 23 Gauge (0,6 mm, blue) for 
subcutaneous emulsion immunization  
Becton, Dickinson and Company, Franklin Lakes  
(New Jersey), USA  
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3.1.5 Software 
3.1.5.1 Data analysis 
 
Description Source 
Adobe Creative Suite (Photoshop, Illustrator)  Adobe Systems, Inc., San Jose, California, USA  
ImageJ /FIJI General Public License 
http://rsbweb.nih.gov/ij/download.html  
Graphpad Prism  GraphPad Software, La Jolla, California, USA  
Microsoft Office (Powerpoint, Excel, Word)  Microsoft Corporation, Redmond, Washington, 
USA  
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3.2 Experimental Animals 
 
All animals were socially housed on 12-h light/dark cycle under controlled standard conditions in 
the animal facilities of the institution. The animals were kept in Eurostandard Type II long cages 
365x207x140 mmH (Tecniplast, Hohenpeißenberg, Germany) stored in IVC rack system with a 
maximum of five mice per cage. Autoclaved food (regular food “Maus” from Ssniff, Soest, 
Germany) and autoclaved tap water were supplied ad libitum. All animal experiments were 
performed in accordance with regulations of the animal welfare act and protocols approved by 
the Regierung von Oberbayern (permit number 55.2-1-54-2532-64). 
For the experiments adult female and male wild-type and several transgenic mice lines were 
used (between 6 – 12 weeks of age).  
In particular, C57/Bl6 were purchased from Janvier Labs. B6.Tg(Thy1-CERTNL15)/Griesb were 
provided by Oliver Griesbeck (MPI for Neurobiology, Martinsried). They express the 
corresponding GECI protein CerTNL15 (Heim and Griesbeck, 2004; Heim et al., 2007) under 
the neuronal expression cassette Thy-1.2 on a C57Bl/6 background. This mouse line allowed 
the investigation of calcium dynamics within axons in healthy and EAE mice. Therefore the 
following transgenic mouse lines were crossed with B6.Tg(Thy1-CERTNL15)/Griesb and 
maintained on this genetic background, if not indicated otherwise.  
To investigate the involvement of TrpM4 in axonal disintegration in EAE lesions, trpM4tm1.1Knt 
mice were used (first described by (Vennekens et al., 2007)). This mouse line was kindly 
provided by Manuel A. Friese and maintained on a C57Bl/6J background. The knockout is a 
result of a targeted genetic deletion of the exons 15 and 16 from the gene locus. For the 
calcium imaging experiments TrpM4-/- animals were crossed with CerTNL15 mice. As control 
group littermate mice heterozygous for TrpM4 were chosen.  
B6.129X1-Sarm1tm1Aidi/Ker were used for the Sarm1-/- experiments. The knock-out of Sarm1 
in this strain is a result of a targeted disruption of exon 3 through 6 of this gene. This mouse 
strain was first described by Kim et al (Kim et al., 2007) and we received this strain as a gift 
from Marc R. Freeman. As control CerTNL15 positive Sarm1+/- littermates were used. For the 
initial characterization experiments performed by Catherine Sorbara Sarm1-/- were crossed to 
B6.Cg-Tg(Thy1-YFP)16Jrs/J, to obtain mice with an axonal labeling.  
ΔNLS R213AR215A WldS mice (Beirowski et al., 2009) were crossed to CerTNL15 and F1 mice 
positive for CerTNL15 and ΔNLS were used for experimental analysis. The mouse line was 
kindly provided and bred at the animal facilities of Thomas Misgeld (Institute of Neuroscience, 
TUM. 
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3.3 Methods 
3.3.1 Induction of experimental autoimmune encephalomyelitis (EAE) 
 
Mice with a C57J/Bl6 background were immunized as previously described (Abdul-Majid et al., 
2000). Briefly, mice were injected with a total of 250 µL of an emulsion of 300 – 400 µg of 
purified recombinant myelin oligodendrocyte glycoprotein (MOG, N1-125, expressed in E. coli) 
in complete Freund’s adjuvant with 5 – 10 mg/mL mycobacterium tuberculosis H37 Ra. The 
solutions were mixed very thoroughly to obtain a thick emulsion that does not disperse in water. 
Directly and 48 h after immunization the mice were given 300 – 400 ng of pertussis toxin (Ptx) 
intraperitoneally. Mice were weighed daily and the severity of behavioral and neurological 
deficits was observed. A standardized clinical EAE scoring system was used (see table 1). On 
average, 10 days after immunization the mice showed weight loss and the day after first clinical 
signs of EAE. 
Score Clinical symptoms 
0 no detectable clinical signs 
0.5 partial tail weakness 
1 tail paralysis 
1.5 gait instability or impaired righting ability 
2 hind limb paresis 
2.5 hind limb paresis with dragging of one foot 
3 total hind limb paralysis 
3.5 hind limb paralysis and fore limb paresis 
4 hind limb and fore limb paralysis 
5 death 
Table 1. EAE clinical scoring scale. 
 
3.3.2 Tissue processing and immunohistochemistry 
 
Animals were lethally anesthetized with isoflurane and perfused transcardially with 25 mL 
1xPBS/Heparin solution followed by 30 mL 4 % PFA in 0.1 M phosphate buffer for uniformly 
preservation of the tissue. After dissection, the tissue was post-fixed in 4 % PFA overnight at 
4°C. The microdissected CNS was cryoprotected in 30 % sucrose in 1xPBS for 24 – 72 h, 
depending on the tissue, before the region of interest was embedded in Tissue-Tek optimal 
cutting temperature (O.C.T.) compound and frozen at – 20 °C. Before immunohistochemistry 
the tissue was sectioned using a cryostat.  
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3.3.2.1 Characterization of axonal morphology within EAE lesions 
 
For the assessment of axonal morphology 50 µm thick longitudinal sections at L3/L4 were 
obtained and stained free-floating. Subsequently, the sections were rinsed three times with 
1xPBS for 10 minutes at room temperature and incubated for blocking in 20 % goat serum in 
1xPBS with 0.5 % TritonX-100 for 1 hour at room temperature. The nuclei were visualized with 
Nissl-staining Neurotrace NT640/660 (1:500) for 30 min at room temperature. The samples 
were mounted with Vectashield and covered with a coverslip glass sealed with nail polish.  
 
3.3.2.2 Characterization of immune cell distribution within EAE lesions 
 
For the CD3 and Iba1 staining 50 µm thick longitudinal sections at L3/L4 were stained free-
floating. The sections were washed in 1xPBS three times for 10 min. For a sharper staining an 
antigen retrieval with sodium citrate was performed. Briefly, sections were incubated in pre-
heated Sodium Citrate Buffer for 30 min at 85 °C. Then the sections were rinsed three times in 
1xPBS/0.5 % TritonX-100, before they were blocked in 20 % goat serum in 1xPBS/0.5 % 
TritonX-100 for 1h at room temperature. After that, the sections were incubated at 4 °C 
overnight with the following primary antibodies: rat anti-CD3 (1:250, Invitrogen) and rabbit anti-
Iba1 (1:250, Wako). After washing the sections three times with 1xPBS/0.5 % TritonX-100, the 
secondary antibodies anti-rat AlexaFluor594 (1: 500, Invitrogen), anti-rabbit AlexaFluor647 (1: 
500, Invitrogen) and NT640/660 (1:500, Invitrogen) were applied for 4 h at room temperature. 
After mounting with Vectashield the sections were covered with a coverslip glass and sealed 
with nail polished.  
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3.3.3 Confocal microscopy 
 
Fixed tissue samples previously stained were scanned on a FV1000 confocal system mounted 
on an upright BX61 microscope (Olympus). The system was equipped with a 10x/0.4 water 
immersion objective, 20x/0.85 and 60x/1.42 oil immersion objectives, and with standard filter 
sets. Recorded 12-bit Images were processed with ImageJ or Adobe Photoshop. 
 
3.3.4 Surgery procedures 
3.3.4.1 Dorsal hemisection injury 
 
As a positive control for Wallerian-like degeneration, we used the dorsal hemisection injury 
model. Mice were anesthetized with an i.p. injection of MMF and given 15 µL of Metacam. The 
cranial spinal cord was exposed with a laminectomy at C4 level and the dorsal spinal cord was 
transected using a very fine pair of scissors (iridectomy scissors) as previously described (Lang 
et al., 2012; Lee and Lee, 2013). Muscle tissue was sewed together and the wound was closed 
with staples. After the surgery, the animals were kept on a heating pad until fully awake, 
rehydrated and treated with Metacam twice per day for 48 hours.  
 
3.3.4.2 Osmotic pump implantation 
 
For chronic treatment with Calpain Inhibitor 3, osmotic pumps were implanted subcutaneously 
in mice with EAE 1 day after onset. For the experiment, the 1007D model of Alzet osmotic 
pumps was chosen. The average pump rate is 12 µL per day and with a total capacity of 100 µL 
can be in use for more than 7 days.  
In short, mice were anesthetized with MMF one day after onset of the clinical symptoms of EAE. 
To access the intervertebral space the caudal lumbar vertebral column was opened. A hole was 
pinched into the dura and the catheter was slowly inserted below the dura while pointing 
caudally to avoid trauma to the spinal cord. The catheter tube was fixed to the vertebral muscle 
tissue at two places to avoid a displacement. The osmotic pump was connected to the 
intraspinal catheter and placed into a skin pocket. The osmotic pumps were filled with 0.1 mL 
2mM CI3 in 10 % DMSO in saline or vehicle solution (10 % DMSO in saline) and incubated over 
12 hours prior to implantation in saline at 37 °C as recommended by the supplier. After the 
wound was closed, the mice were rehydrated with 1 mL of s.c. injected Ringer’s solution, left for 
recovery on a heating pad and given 0.1 mL temgesic. After 5 days of treatment, the mice were 
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perfused transcardially with 4 % PFA. To evaluate the success of delivery, the pumps were 
weighed and the residual volume was measured.  
 
3.3.5 2-Photon in vivo imaging 
 
According to previously established protocols (Kerschensteiner et al., 2005; Misgeld et al., 
2007; Romanelli et al., 2013) mice were intraperitoneally anaesthetized with MMF. After 
anaesthesia, the fur above the lumbar spinal cord, the right hindlimb and above the throat was 
shaved. To stabilize the breathing rate and to reduce breathing artefacts a tracheotomy was 
performed. Therefore, the mouse was fixed in a supine position and after a tracheotomy the 
tracheal tube of a breathing device is inserted. With a few stitches the tube was secured. Then 
the mouse was carefully turned around, fixed again and with a dorsal laminectomy the spinal 
cord was exposed. Two to 3 vertebrae were removed during the surgery. To clean and moist 
the spinal cord it was constantly rinsed with prewarmed aCSF. Afterwards the vertebral column 
was fixed using a spinal clamping device, which allows controlled movement in x,y and z. axis 
during imaging. To monitor for vital parameter a thigh sensor was clipped on the shaved 
hindlimb. To allow immersion of the objective a well consisting of 3 % Agarose/aCSF was built 
around the exposed spinal cord. The agarose well allowed to hold aCSF throughout the 
complete imaging session and to incubate the spinal cord with intravital dyes (Romanelli et al., 
2013).  
Only animals with a score higher than 2.5 were used for imaging to ensure to find proper 
lesions. Prior to imaging the clamped and exposed spinal cord was incubated with Neurotrace 
640/660 (1:500) to visualize the density of nuclei to define a lesion. Several lesion sites were 
imaged repetitively every 2 hours to follow the axonal morphological changes. To ensure that 
the anesthesia is deep enough, the breathing rate and oxygenation was controlled constantly. 
When the depth of anesthesia dropped, the mouse was injected with additional 0.1 mL MMF. 
The images were acquired with a 25x/1.25 water immersion objective at 1024x1024 pixel 
resolution and with a pixel dwell time of 2 µs/pixel.  
For the calpain inhibition experiments, the mice were treated with 0.1 mL 100 nM calpain 
inhibitor III (CI3) in 0.5 % DMSO or 0.1 mL vehicle solution (0.5 % DMSO) 30 min prior to 
imaging. During imaging the immersion fluid consisted of CI3 solution or vehicle solution in 
aCSF to ensure constant presence of the treatment during experiments. The solution renewed 
every 2 hours.  
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To control for phototoxicity, damage caused during surgery and dye toxicity the same procedure 
was performed with healthy animals. After several hours of imaging no morphological changes 
in the axons were observed.  
3.3.6 Data evaluation and Statistics 
 
For data processing and analysis Adobe Photoshop CS6 and FIJI (http://fiji.sc/Fiji) were used. 
Statistical analysis of the experimental data was performed with GraphPad Prism 7.01. 
 
3.3.6.1 Axonal pathology after dorsal hemisections in Sarm1 and ΔNLS- WldS animals 
 
To validate the neuroprotective properties of Sarm1 and ΔNLS- WldS transgene, the axonal 
morphology was evaluated 3 days after dorsal hemisection. Four to 6 images of the cervical 
dorsal spinal cord 200 – 600 µm cranially from the injury site were taken per animal. As an 
internal control for tissue damage due to the surgical procedure, images were taken as well 
from the opposite ventral part. No damage was observed in these areas. The first 50 axons 
dorsal to ventral were evaluated and classified into stage 0, 1 and 2 axons (according to (Nikić 
et al., 2011)). Three animals per group were analyzed.  
 
3.3.6.2 In vivo analysis of calcium signals and dynamic analysis 
 
As already described (Schumacher, 2016) the ratio of YFP/CFP signal was used to estimate the 
intra-axonal calcium concentration. In short, images of the first timepoint were opened using the 
Bioformats Importer plugin of ImageJ as two separate channels showing the CFP and FRET 
signals separately. In one of the two channels, ROI were selected within an identified axon and 
adjacent to that outside of that axons a background ROI was selected. The intensity ratio within 
one axon did not vary much, therefore only one ROI was drawn within an axon. The diameter 
was measured at three distinct sites of one axon. The same ROIs were transferred to the other 
channel to obtain the corresponding intensities. To calculate the intensity ratio the following 
formula was used (adapted from (Schumacher, 2016)): 
      
              
              
    
With YFP representing fluorescence intensity of yellow fluorescent protein variants and CFP 
standing for fluorescence intensity of blue fluorescence protein variants. The bleedthrough 
factor (BF) is an experimentally measured value. Since this factor does not change the intensity 
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ratio itself and I was only interested in the qualitative changes of the intraaxonal changes, the 
BF correction was not applied. 
For the lesion characterization in vivo for Sarm1 and ΔNLS-WldS experiments, the intensities 
and the respective background of the first 30 axons from dorsal surface of the spinal cord were 
measured and their morphology was noted, according to the stages previously introduced (Nikić 
et al., 2011). 
In case of the TrpM4 experiment, calpain inhibition and analysis of the dynamic transitions, the 
fluorescence ratios and axonal morphologies were obtained from the first 80 axons from dorsal 
surface of the spinal cord. In case less than 80 axons were identified within one lesion, axons 
were further identified in another lesion of the same animal. After reaching 80 axons, only 
stage0 and stage1 axons were evaluated, in order to increase the size of the high calcium 
cohort for the further dynamic analysis.  
Changes in intra-axonal calcium level and axonal morphology were traced 4 hours after the first 
imaging timepoint. Since I was interested in the fate of axons with increased intra-axonal 
calcium only those axons were followed over time. Axons were relocated in the second 
timepoint based on their position to peculiar anatomical structures like blood vessels. The 
dynamic rates were calculated as following: 
    
                              
                                             
 
    
                         
                                            
 
    
                                   
                                            
 
    
                                           
                                                  
 
There are several transitions possible. Healthy appearing, high calcium axons could develop 
swellings. These transitions are reflected with the swelling rate. As fragmentation, we consider 
only the transition of high calcium stage 1 axons that fragment after 4 h. There are as well 
recovery processes detectable, as it was already seen in previous experiments (Nikić et al., 
2011; Schumacher, 2016). As recovery, we consider all transitions that improved either the 
morphology or the calcium level of the observed axons. Since the mechanisms involved in 
calcium level decrease and deswelling are probably distinct from each other, we differentiated 
two different recovery rates: rate of decreased calcium (rCD) and rate of morphology 
improvement (rMR). An overview of all transition of interest are depicted in Figure 6. 
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Figure 6. Overview of transition of interest. 
Axons are classified by their morphology as normal appearing axons (stage 0), swelling (stage 1) or 
fragments (stage 2) or based on their [Ca
2+
]cyt levels as high calcium (yellow) or low calcium axons 
(magenta). Possible transitions that high calcium populations undergo, are either fragmentation from 
stage1
high
 to stage2 (FR=fragmentation rate), swelling from stage0
high
 to stage1
high
 (SR=swelling rate). A 
decrease in cytosolic calcium (CD=rate of calcium decrease) or a morphological recovery (MR=rate of 
morphological recovery) are considered as recovery processes. Adapted from (Schumacher et al., 2016). 
 
To obtain reliable transition rates I introduced several evaluation criteria to optimize the analysis 
and ensure that at least 25 axons (stage 0 and stage 1) with increased intra-axonal calcium at 
timepoint 0 were available for the calculation of the transition rates. 
 
3.3.6.3 Axonal morphology within EAE lesions in fixed tissue 
 
The analysis of axonal stages in chronic fixed EAE tissue was performed on confocal images 
obtained with a 60x/objective. After identifying the lesion area based on infiltrating cells stained 
with Neurotrace a line of 500 µm length was drawn from the lesion border. Using the cell 
counter plugin of ImageJ axons crossing this line were classified according to their morphology 
into stages. Stage 0 axons are normal appearing, undisrupted axons, whereas stage 1 axons 
display at least one swelling. As soon as an axon shows a disruption it was classified as stage 
2. When at least 3 fragments were lying in proximity to each other on a virtual line, there were 
as well counted to the stage 2 axons.  
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3.3.6.4 Evaluation of lesion load 
 
Overview images of coronal spinal cord sections were taken with a 20x objective at the confocal 
microscope. Lesion area was defined based on the Neurotrace staining. Using the polygon 
selection tool of ImageJ the whole section, white matter and areas occupied by infiltrating cells 
within the grey matter were outlined. Area of white matter was calculated by subtracting the 
grey matter area from outline area. The lesion load is determined as the ratio of area occupied 
by infiltrating cells to white matter area. For the evaluation 2 – 3 sections were used per animal.  
 
3.3.6.5 Evaluation of cell composition 
 
For evaluation of immune cell composition, coronal spinal cord sections were stained with 
antibodies against CD3 and Iba1. The infiltrating cells within the CNS were visualized by 
Neurotrace staining. Two lesions of 3 section per animal were analyzed in a blinded fashion. 
For every lesion, the lesion area was measured and the numbers of CD3 positive and Iba1 
positive cells within the lesion were counted. Lesion area was assessed based on Neurotrace 
staining in a maximum intensity z projection of the image that was obtained with a 60x objective 
on the confocal microscope. This area was furthermore used to identify the lesion.  
For analysis of cell composition, the cell counter plugin in ImageJ was used. To reduce counting 
mistakes due to staining artefacts only the middle planes of a z-stack were used. To assess the 
numbers of microglia within a lesion, the NT and Iba1 positive cells were counted. Mature T cell 
were identified based on the positive CD3 staining. The cell composition within the lesion is 
shown as cell density, calculated as cell number normalized to the lesion area. 
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4 Results 
4.1 In vivo imaging of axonal calcium levels and dynamics in vivo 
 
In previous experiments my colleague Adrian-Minh Schumacher followed the fate of axons in 
healthy and EAE induced animals expressing the calcium sensor CerTNL15 in neurons. Due to 
the characteristics of the calcium sensor it is possible to measure the calcium concentration 
through ratiometric imaging. It was found that in healthy axon in non-EAE mice the intra-axonal 
calcium concentration is tightly controlled (Figure 7). In EAE lesions, more about one third (25.1 
± 6.8 %) of swollen axons (stage 1) show increased calcium levels. Interestingly, also normal 
appearing axons (stage 0) show increased intra-axonal calcium (8.3 ± 2.8 %).  
 
Figure 7. Axonal calcium levels in healthy axons and in axons in acute EAE lesions (Witte et al., 
submitted).  
Distribution of cytosolic calcium levels of single axons in healthy and acute EAE mice, displayed 
by YFP/CFP channel ratios and normalized to the mean of control axons. Axons with intensity ratios +3 
SD above the control mean (visualized as color-coded threshold) were defined as axons with elevated 
calcium. On the top: Percentages represent the number of axons with elevated [Ca
2+
]cyt,, shown as mean 
± SEM, grouped in the different stages of degeneration (tested per animal in n=6 control and n=11 EAE 
mice, Kruskal-Wallis followed by one-sided Mann-Whitney U post-hoc tests). * p < 0.05 and *** p < 0.001.  
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To investigate whether calcium influences the probability of axons to degenerate, their changes 
in morphology and calcium levels in EAE lesions were followed over time. The observed 
transitions are summed up in Figure 8. Axons with higher calcium levels are more likely to swell 
(16 % vs. less than 1 %) and to fragment (19 % vs. 4 %), compared to axons with normal 
calcium levels. Recovery of axons from stage 1 was already observed in EAE lesions in earlier 
experiments (Nikić et al., 2011). Axons with lower calcium levels are more probable to recover 
than axons with high calcium levels (6 % vs. 3 %). These observations lead to the conclusion 
that calcium is likely to be involved in the degradation process of axons in acute EAE. 
Before addressing this hypothesis with different transgenic lines or drug treatment, it was 
necessary to reproduce the results with control animals used in the following project, using the 
same surgical and imaging methods. I compared the axonal staging of 8 EAE animals used in 
the experiments that were performed by Adrian-Minh Schumacher (described above) with the 
distribution of axonal morphology of the EAE animals that I used as controls for this project (see 
Figure 9A). The axonal morphology was determined for a representable axon number within 
several lesions separately. The mean distributions across all lesions within one animal were 
displayed in the graph. There were no statistically significant differences observed using a chi-
square test between the previous data set (stage 0: 64.18 ± 3.75 %, stage 1: 20.45 ± 3.36 %, 
stage 2: 15.45 ± 2.22 %) and the control data set that I obtained (stage 0: 59.89 ± 0.98 %, stage 
1: 22.25 ± 1.57 %, stage 2: 17.85 ± 1.25 %).  
  
Figure 8. Diagram showing mean transition probabilities (per hour and axons).  
Mean transition probabilities of axons between morphological changes per observed ‘axon hour’ in 
high [Ca
2+
]cyt (yellow) and low [Ca
2+
]cyt axons (magenta). Symbols represent FAD stages 0 (normal appearing), 
1 (swollen) and 2 (fragmented). n=277 axons in 8 animals. Adapted from (Schumacher, 2016) and (Witte et al., 
2018, submitted).  
Results 
 
 
48 
  
Next, I compared the fragmentation rates of axons with high calcium of each animal from the 
previous experiments and the control groups in my experiments, since in this thesis I am mainly 
focusing on the mechanisms that lead to axon degeneration in EAE (see Figure 9B). The 
transition rates have a large spread. The fragmentation rates observed by my colleague (0.120 
± 0.05) is not significant different from the fragmentation rates of all EAE animals that were used 
as control groups in the single experiments (0.168 ± 0.02). Comparing the single different 
transgenic lines with the previous results shows no significant difference as well (Sarm1+/-: 
0.212 ± 0.03, TrpM4+/-: 0.170 ± 0.03, CerTNL15: 0.145 ± 0.03).  
Herewith, I could reproduce the previous experimental data. Since F1 TrpM4+/- x CerTNL15 
and Sarm1 +/- x CerTNL15 appear to be similar to F0 CerTNL15 animals, I can assume that the 
heterozygous deletion of Sarm1 and TrpM4 alleles in these mice has no observable influence 
and can be used in the following experiments as valid littermate control groups. 
  
Figure 9. Previous experimental data on axonal morphology and fragmentation probabilities could be 
reproduced. 
A) Comparison of the mean frequency (in % ± SEM) of axon stages in EAE lesions, as observed 
in previous experiments (n = 8, all CerTNL15) and in EAE animals used as control in this project (n = 17, 
n = 5 Sarm1+/- x CerTNL15, n = 3 TrpM4 +/- x CerTNL15 and n = 9 CerTNL15). There is no significant 
difference observable (chi-square test, p = 0.9807). B) Comparison of the fragmentation rates measured 
in previous experiments (n = 8, all CerTNL15) and measured in the control EAE animals used in this 
thesis (n = 18 control, n = 5 Sarm1+/- x CerTNL15, n = 3 TrpM4+/- x CerTNL15, and n = 10 CerTNL15). The 
cohort of all EAE control groups are pooled together as control. With a one-way ANOVA with adjusted p-
value due to multiple comparisons there were no statistical significant differences between groups 
observable.  
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4.2 Wallerian-like degeneration pathways show no major contribution to 
neuroinflammatory axon degeneration in vivo 
4.2.1 ΔNLS-WldS and Sarm1-/- protect against Wallerian degeneration 
 
To have a readout for the calcium concentration we crossed the previously described lines of 
Sarm1-/- and ΔNLS-WldS with CerTNL15. For experiments the F1 generation that is positive for 
CerTNL15 as determined via PCR was used for experiments. As already mentioned, I used 
Sarm1+/- x CerTNL15 as control group for Sarm1-/- x CerTNL15. The control group for ΔNLS-
WldS consisted of littermates negative for the ΔNLS-WldS gene, but positive for CerTNL15. 
Before investigating the effect of these transgenic mouse lines in EAE, we performed a dorsal 
hemisection and assessed the extent of Wallerian degeneration to validate the protective 
capacity of Sarm1-/- and ΔNLS-WldS in the spinal axon population that we subsequently studied 
in EAE. The axonal morphology was assessed 3 mm rostral from the lesion site three days after 
the injury. Representative images of the dorsal hemisection lesion are shown in Figure 10.  
The first 30 axons from the lesion border were classified by their morphology into fragmented 
and intact axons. Both healthy appearing and swollen axons were considered as intact axons. 
The results are displayed in Figure 10. In both control groups only 30 % remained intact, 
whereas most of the axons fragmented 3 days post injury (Sarm1+/-: intact – 32.11 ± 5.75, 
fragmented – 62.63 ± 36.48; CerTNL15: intact – 31.63 ± 3.90, fragmented: 68.5 ± 3.88). In the 
presence of the protective ΔNLS-WldS around 80 % of the axons survived the insult (ΔNLS: 
intact – 74.82 ± 1.948, fragmented – 25.06 ± 1.96). A similar result was observed in Sarm1-/- 
mice. 70 % of the axons remained intact (Sarm1-/-: intact – 70.46 ± 3.47, fragmented – 29.54 ± 
3.47). The transgenic CerTNL15 mouse lines either lacking Sarm1 or overexpressing ΔNLS-
WldS are therefore delaying Wallerian fragmentation in a spinal cord lesion model. 
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Figure 10. Positive control for Wallerian-like Degeneration 
A – D) Representative confocal images of the cervical spinal cord of animals 3 days after dorsal 
hemisection. (A) ΔNLS-WldsxCerTNL15, B) Sarm1-/-xCerTNL15, C) CerTN D) Sarm1+/- x CerTNL15). The 
black scale bar represents 20 µm. E) Quantification of intact and fragmented axons 3 days after dorsal 
hemisection in ΔNLS-WldsxCerTNL15 and littermates CerTNL15 (mean ± S.D, n=3 for each group, one-way 
ANOVA with multiple comparisons p = 0.0456). F). Quantification of intact and fragmented axons 3 days after 
dorsal hemisections in Sarm1-/-xCerTNL15 animals and control littermates Sarm1+/-xCerTNL15 (mean ± S.D, 
n=3 for each group, one-way ANOVA with multiple comparisons p = 0.0237). Since all data groups passed the 
normality test according to Shapiro-Wilk the two-sided student’s t test was used for statistical analysis, * p < 
0.05. 
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4.2.2 ΔNLS-WldS and Sarm1 do not ameliorate clinical disease course of EAE 
 
After I demonstrated that the used transgenic lines present indeed axonal protective features in 
a spinal cord injury model, I investigated whether the ΔNLS-WldS or Sarm1-/- modulate the 
pathogenesis of MOG-induced EAE.  
After EAE induction mice were weight and scored daily. The clinical disease progression is 
visualized in the following diagrams. 
 
Figure 11. Acute clinical disease score of ΔNLS-Wld
S
 and Sarm1-/- mice 
A) Clinical disease score assessed daily after immunization of ΔNLS-Wld
S
 (n = 15) and their wildtype 
littermates (n = 16), column p=0.5546. B) Clinical EAE score assessed daily after immunization of Sarm1-/- x 
Thy1YFP (n = 10) and littermates Sarm1+/- xThy1YFP mice (n = 10), p=0.9320. In both disease scores no 
significant difference was observable, as assessed by repeated measures two-way ANOVA. 
 
ΔNLS-WldSxCerTNL15 mice did not show a significant difference in their disease onset and at 
acute EAE compared to their CerTNL15 positive littermates negative for ΔNLS.  
There is as well no significant difference observable between Sarm1-/- and control mice, in the 
acute phase and in the chronic phase (data not shown). It has to be noted, that the animals in 
the WldS group appeared less sick than the Sarm1 animals. Both groups were bred and housed 
in a different environment, which might have had an influence in the disease severity. 
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4.2.3 Immune cell infiltration and axonal morphology is unchanged in chronic 
EAE lesions of Sarm1-/- mice 
 
Although we did not observe any differences in the clinical progression of EAE, we tested for 
differences in the lesion load in the chronic phase and differences in axonal morphology in 
chronic lesions of Sarm1-/- group.  
 
Figure 12. Infiltrations spread and axonal staging in chronic lesions. 
A) Lesion load measured as area occupied by infiltrating cells in the white matter, displayed as 
percentage mean ± SEM (n = 5 Sarm1-/-; n = 5 Sarm1+/-, control). Since both data groups passed the 
normality test according to Shapiro-Wilk the two-sided, unpaired student’s t test was used for statistical 
analysis. No statistical difference was observable, p=0.6967. B) Distribution of axonal morphology within 
older lesions 32 days after EAE induction (n = 11 Sarm1-/-, n = 9 Sarm1+/-). Data sets passed the normality 
test according Shaphiro-Wilk. There was no statistical difference observable using chi-square test 
(χ
2
=0.6618, p=0.7183). 
 
To assess the lesion load we measured the occupancy of infiltrating cells within the white matter 
in Sarm1-/- x Thy1YFP tissue and in the control groups Sarm1+/- x Thy1YFP that were 
sacrificed 32 days after EAE induction. As Figure 12 shows there is no significant difference 
between the control (19.95 ± 4.02 %) and the Sarm1-/- group (22.84 ± 5.91 %). 
The axonal distribution within chronic EAE lesions (32 days after EAE induction) was 
comparable between Sarm1-/- mice and their control group.  
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4.2.4 Axon degeneration stages are unaltered in acute EAE lesions in ΔNLS-WldS 
and Sarm1-/- mice 
 
In the acute phase 2-3 days after onset of EAE symptoms, the disability of mice reaches its 
peak. I characterized the distribution of axonal damage stages in the lumbar spinal cord within 
acute lesions to be able to see if delaying Wallerian-like degeneration has an effect on axonal 
degeneration. Figure 13 displays the results from this characterization.  
In the Sarm1-/- group there is no difference in appearance of normal appearing (stage 0) axons 
(Sarm1-/-: 61.28 ± 1.77 % vs Sarm1+/-: 59.89 ± 1.43 %), swollen (stage 1) axons (Sarm1-/-: 
20.71 ± 2.92 % vs Sarm1+/-: 22.25 ± 2.29 %) or fragmented (stage 2) axons (Sarm1-/-: 18.01 ± 
2.43 % vs Sarm1+/-: 17.85 ± 1.82 %). The same is observed in the ΔNLS-WldS group (ΔNLS: 
65.58 ± 2.31 % vs CerTNL15: 60.88 ± 2.71 % for stage 0 axons, ΔNLS: 22.16 ± 2.02 % vs 
CerTNL15: 23.42 ± 2.08 % for stage 1 axons and ΔNLS: 11.26 ± 1.80 % vs CerTNL15: 14.45 ± 
1.71 % for stage 2 axons). This suggests that the presence of ΔNLS+ has not an axonprotective 
effect in acute EAE lesions, at least on the morphological level.  
 
Figure 13. Axonal damage in acute EAE lesions in Sarm1-/- and ΔNLS-Wld
S
 animals.  
A) Distribution of axonal damage stages at onset+2 or onset+3 (acute EAE) in Sarm1-/- x CerTNL15 
(n = 10) and their littermate control Sarm1+/- x CerTNL15 (n = 8) (χ
2
=0.7532, p=0.6826). B) Distribution of 
axonal morphology in axons in acute EAE lesions in ΔNLS x CerTNL15 (n = 9) and ΔNLS negative CerTNL15 
(n = 7). The distribution of axon stages is not significantly different (chi-square test χ² = 0.162, p = 0.9222). 
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4.2.5 ΔNLS-WldS and Sarm1-/- do not alter intra-axonal calcium concentrations in 
vivo 
 
To address, whether Wallerian-like degeneration could influence the calcium regulation within 
axons in EAE, I measured the YFP/CFP ratios of axons that I identified for axonal staging and 
grouped them according to their stages. As a robust detection of elevated calcium levels, I 
defined the cut-off value for YFP/CFP ratios based on the mean +3SD of the ratios measured in 
control animals. In previous experiments it was observed that around 16 % of the healthy 
appearing axons have increased intra-axonal calcium levels, even a higher percentage of 
swollen axons (about 50 %) show an increase in calcium. This I can observe as well in Sarm1 
and ΔNLS groups. 10.02 ± 4.076 % stage 0 axons in Sarm1-/- mice and 17.9 ± 6.043 % stage 0 
axons in Sarm1+/- mice have calcium levels above the cut-off (normalized to healthy control 
animals, population means ± SEM: Sarm1-/-: 1.01 ± 0.01 vs Sarm1+/-: 1.21 ± 0.01). One third 
(31.09 ± 7.439 % for Sarm1-/- and 36.91 ± 8.97 % for Sarm1+/-) of swollen axons in these mice 
are classified as calcium high axons (population means ± SEM: Sarm1-/-: 1.21 ± 0.03 vs 
Sarm1+/-: 1.38 ± 0.03). About two third (67.27 ± 7.53 % for Sarm1-/- and 69.35 ± 4.83 % for 
Sarm1+/-) of stage 2 axons have increased calcium levels (population means ± SEM: Sarm1-/-: 
1.38 ± 0.04 vs Sarm1+/-: 1.68 ± 0.06). Using Shapiro-Wilk test I found that the data sets were 
not normally distributed. Therefore, I used the Mann-Whitney test with Bonferroni-Dunn post 
hoc adjustment of p-value to find that there is no significant difference observed in in healthy 
Sarm1-/- and Sarm1+/- animals regarding intra-axonal concentrations. Nevertheless, it needs to 
be noted that in EAE Sarm1-/- animals the intra-axonal levels are less increased as compared 
to EAE Sarm1+/- animals.  
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Figure 14: Distribution of calcium levels in axons in acute EAE lesions in Sarm1-/-and ΔNLS-Wld
S
 mice. 
A) Distribution of intra-axonal calcium concentration measured as YFP/CFP ratio at beginning of 
2PM imaging in Sarm1-/- and control Sarm1+/- mice (Sarm1-/- n = 4, Sarm1+/- n = 9). B) Distribution of 
cytosolic calcium concentration at beginning of 2PM imaging in ΔNLS+ and control mice (ΔNLS+ n = 9, 
ΔNLS- n = 7). No statistically significant difference was observed using Mann-Whitney U test following 
Bonferroni-Dunn post-hoc correction. 
 
The distribution of intra-axonal calcium concentration in axons of ΔNLS+ animals behaves 
similar. The mean intra-axonal calcium concentration rises with the damage, but it is not 
significantly different between ΔNLS and control group after using Bonferroni-Dunn corrected 
Mann-Whitney test as normal distribution of data could not be confirmed using Shapiro-Wilk 
test: The mean cytosolic calcium levels are very similar between both groups: ΔNLS+: 1.0 ± 
0.01, n = 864 vs CerTNL15: 0.97 ± 0.01, n = 674 for stage 0 axons; ΔNLS+: 1.28 ± 0.03, n = 
244 vs CerTNL15: 1.07 ± 0.02, n = 228 for stage 1 axons and ΔNLS+: 1.51 ± 0.03, n = 171 vs 
CerTNL15: 1.36 ± 0.04, n = 165 for stage 2 axons. As well the fraction of calcium high axons is 
very comparably within lesions of ΔNLS+ and ΔNLS- animals. In ΔNLS+ mice 8.8 ± 3.1 % of 
stage 0 axons are classified as high calcium axons and about the same fraction (7.9 ± 2.7 %) of 
stage 0 axons have elevated calcium levels in the control group. 21.6 ± 9.0 % of stage 1 axons 
in ΔNLS+ mice and 17.8 ± 5.7 % of stage 1 axons in control mice are elevated in calcium, 
whereas again about two thirds of stage 2 axons are categorized as high calcium in both groups 
(ΔNLS+: 67.0 ± 9.3 % and ΔNLS-: 70.0 ± 6.4 %).  
  
Results 
 
 
56 
  
4.3 The effects of TrpM4-/- on EAE needs further investigation 
4.3.1 TrpM4-/- has no effect on clinical disease course 
 
To assess, whether genetical depletion of the TRPM4 channel alters clinical disease 
course of EAE, we monitored TrpM4-/- and their control group TrpM4+/- mice daily for 
35 days after immunization. The clinical course of these mice is shown in figure 15. 
There is no significant difference observable between TrpM4-/- and control, neither in 
the acute phase directly after disease onset, nor in the chronic phase of the disease.  
  
Figure 15. Clinical EAE progression in TrpM4-/- x CerTN and TrpM4+/- x CerTN mice. 
The animals were scored daily from the day of immunization over 35 days. There is no 
significant difference observable between TrpM4-/- (n = 10) and their littermate controls (TrpM4+/-, n = 
10), tested with a two-way ANOVA with a multiple measures p value adjustment, p=0.5196).  
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4.3.2 The influence of TrpM4 on axon degeneration in EAE requires further study 
 
We used our in vivo imaging approach to assess axon damage stages and intra-axonal calcium 
levels in acute EAE lesions in TrpM4-/- animals. Again, only mice with a clinical score higher 
than 2 were selected. As already described previously, we characterized the axons within the 
EAE lesions regarding their morphology and calculated the calcium ratios. The results are 
displayed in Figure 15.  
 
Figure 16. Axonal morphology and calcium distribution in TrpM4-/- and controls 
A) Distribution of axonal stages within an animal in acute EAE in TrpM4+/- x CerTNL15 (n = 5) and 
TrpM4-/-xCerTNL15 (n = 5) animals. B) Distribution of intra-axonal calcium concentration within an acute EAE 
lesion in TrpM4+/- x CerTNL15 (n = 5) and TrpM4-/-xCerTNL15 (n = 5). Mann-Whitney test with Bonferroni-
Dunn correction showed that the differences are not statistically significant.  
 
The overall distribution of axonal morphology in both groups differs compared to previous data 
sets. Here I took a different approach and evaluated 80 axons in total for each animal. In case 
the 80 could not be reached in one lesion, it was filled up with axons from another lesion. The 
lack of the TrpM4 appears to have no influence on the axonal morphology in the EAE lesion. 
The distributions of intact (TrpM4-/-: 33.75 ± 6.9 % vs TrpM4+/-: 37.25 ± 5.6 %), swollen 
(TrpM4-/-: 35.25 ± 5.8 % vs TrpM4+/-: 33.5 ± 5.4 %) or fragmented axons (TrpM4-/-: 31 ± 6.1 % 
vs TrpM4+/-: 29.25 ± 3.0 %) are similar, independent if TrpM4 is present or not.  
The intraaxonal calcium levels, on the other hand, are elevated in the TrpM4-/- group 
throughout all stages, but this observation is statistically not significant (Bonferroni-Dunn 
corrected Mann Whitney test as normal distribution could not be confirmed using Shapiro-Wilk 
test). The means (mean ± SEM) of intra-axonal calcium concentration for the control TrpM4+/- 
animals are 0.90 ± 0.01 (stage 0), 1.06 ± 0.03 (stage 1) and 1.31 ± 0.04 (stage 2). In TrpM4-/- 
animals I measured the following means: stage 0 – 1.07 ± 0.05, stage 1 – 1.33 ± 0.06 and stage 
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2 – 1.53 ± 0.04 (mean ± SEM.). All means are normalized to the intra-axonal concentration 
measured in healthy TrpM4+/- or TrpM4-/- animals. 
In addition, we were interested in the influence of TrpM4 on the fragmentation and swelling 
rates. Therefore, we followed axons and their fate over 4 hours of imaging, as described in 
section 3.3.6.2. The calculated transition rates are summarized in Figure 16. Since applying the 
strict evaluation criteria would leave us with only low animal numbers, I show here animals in 
which I could follow at least 15 high calcium axons in the 4 hour time window, being confronted 
with increased variability in the data sets.  
 
Figure 17. Axonal dynamics over 4 h in EAE TrpM4 animals and their control 
Overview of calculated transition rates during 4 hours of imaging, displayed as events/hour (TrpM4-/- 
n = 4, TrpM4+/- n = 3). Since data values are normally distributed (Shapiro-Wilk) two-sided, unpaired 
student’s t test was used to assess statistical differences between groups. 
 
Both fragmentation rates for TrpM4-/- (0.31 ± 0.11) and TrpM4+/- (0.43 ± 0.05) are in the same 
range. The same is true for the swelling rate (TrpM4-/-: 0.33 0.20 vs TrpM4+/-: 0.24 ± 0.14). 
Although, there is a tendency for higher recovery rates in the TrpM4-/- group (0.40 ± 0.15) 
compared to the TrpM4+/- group (0.17 ± 0.04), this difference is not statistically significant 
(unpaired two-tailed t test, p = 0.2464). These are only preliminary data. Unfortunately, we were 
dependent on harsh evaluation criteria to obtain reliable dynamic rates and therefore, our group 
sizes were reduced to only 2 animals for each group. Furthermore, I pooled all possible 
recovery processes together, because of the low numbers of transitions I could observe during 
imaging. Therefore, more experimental data need to be added to be able to draw conclusions. 
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4.4 Inhibition of calpain ameliorates neurodegeneration in EAE lesions 
4.4.1 Inhibition of calpain results in decreased fragmentation rates in acute EAE 
 
In neurodegenerative disease, calpain is found to be overexpressed and several studies have 
used calpain inhibition to improve disease outcome after EAE induction (Fà et al., 2016; Guyton 
et al., 2005; Hassen et al., 2006; Kling et al., 2017; Machado et al., 2015; Nixon et al., 1994). 
Williams et al. showed that using calpain inhibitor III rescues the axons from fragmentation after 
traumatic injury (Williams et al., 2014). To test whether calpain inhibition exhibits a beneficial 
effect on axon survival in acute EAE, we treated mice with a score of 2.5 and higher during 
imaging with a calpain inhibitor. The exact treatment procedure is described in chapter 3.3.5. 
Beforehand, we characterized the EAE lesion of the groups that were treated with either CI3 or 
vehicle regarding their axonal stage distribution and calcium levels (as previously described). As 
Figure 18(A) and 18(B) indicate, lesions were comparable between groups before treatment 
start concerning calcium levels and axonal damage.  
The axonal staging is based on the first 80 axons that were found in lesions in an animal before 
treatment. Stage 0 axons appeared in the vehicle group (42.36 ± 2.0 %) with the same 
frequency as in the CI3 treated group (44.63 ± 2.7 %). There is as well no significant difference 
observable in the distribution of swollen axons (vehicle: 31.94 ± 3.1 % vs CI3: 33.13 ± 2.8 %). 
The distribution of fragmented axons is similar in vehicle (25.69 ± 2.3 %) and in CI3 group 
(22.25 ± 1.7 %).  
Both groups are very comparable regarding the density of infiltrating cells that were visualized 
within the imaged lesion area in vivo with Neurotrace. Although the CI3 group tends to have 
higher cell densities, there is no significant difference between vehicle treated group (2527 ± 
248 nuclei/mm²) and CI3 treated group (3171 ± 290 nuclei/mm²).  
I measured the YFP/CFP ratios of these axons in untreated lesions and grouped them 
according to their axonal stage. The mean calcium levels of normal appearing axons in both 
groups is comparable (vehicle: 1.02 ± 0.01, 304 axons vs CI3: 1.09 ± 0.01, 400 axons). The 
average calcium level is increased in swollen axons in both groups (vehicle: 1.20 ± 0.03, 228 
axons vs CI3: 1.24 ± 0.03, 286 axons). The calcium concentrations of fragmented axons are 
comparable as well (vehicle: 1.47 ± 0.04, 180 axons vs CI3: 1.38 ± 0,03, 194 axons). I could not 
detect a significant difference with Bonferroni-Dunn corrected Mann-Whitney U test between 
CI3 treated and vehicle treated group regarding the percentage of detected fraction of calcium 
high axons. There were 27.39 ± 7.86 % of stage 0, calcium high axons in CI3 treated mice, 
whereas in vehicle treated mice I detected 17.07 ± 5.07 % of stage 0, high calcium axons. Even 
a higher percentage of high calcium axons were observed in swollen axons: for the CI3 group 
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about half of the axons were increased in intracellular calcium (50.77 ± 6.93), for the vehicle 
group 43.21 ± 5.40 %. Two third of stage 2 axons showed increased cytosolic calcium (CI3 
group: 72.47 ± 5.13 %; vehicle group: 64.85 ± 7.08 %).  
The transitions were determined as determined in previous sections and are depicted in Figure 
18). The transition rates are based on images obtain from lesions during treatment Although the 
recovery (vehicle: 0.21 ± 0.04 vs CI3: 0.30 ± 0.04) and the swelling rates (vehicle: 0.25 ± 0.05 
vs CI3: 0.23 ± 0.05) were not affected by the CI3 treatment, the fragmentation rate of the CI3 
treated groups was significantly reduced (0.25 ± 0.04) compared to the control group (0.40 ± 
0.07). The fragmentation rate of the control group (0.48 ± 0.05), on the other hand, lied in the 
same range as the calculated fragmentation rates of the control populations used in the 
previous experiments, namely TrpM4+/- and Sarm1+/- (see Figure 9(B)).  
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Figure 18. Overview of acute Calpain inhibition.  
A+B) Group Equivalence before treatment start: A) Distribution of axonal stages in acute EAE lesions in vivo 
of vehicle (n = 9) and CI3 treated animals (n = 11) before treatment. Using chi-square test no statistical 
difference could be observed. B) Distribution of intra-axonal calcium concentration before treatment (vehicle 
n = 9, CI3 n = 11). No statistical difference between groups could be observed using Bonferroni-Dunn 
corrected Mann-Whitney U test.  
C-F) After treatment: C) Overview of calculated transition rates during 4 hours of imaging and treatment, 
displayed as events/hour (vehicle n = 9, CI3 n = 11). Since data values are normally distributed (Shapiro-Wilk) 
two-sided unpaired student’s t test was used to assess statistical differences between groups. * p < 0.05. D) 
Overview of possible transitions. Of particular interest are the transitions of axons with high cytosolic 
calcium: swelling (SR) and fragmentation (FR). Recovery events can be differentiated in morphological 
recovery (MR) or calcium decrease (CD). E) Densities of infiltrating cells within the imaged lesion site in vivo 
of vehicle (n = 9) and CI3 treated animals (n = 11) at first imaging time point. F) The dynamic rates of vehicle 
and the CI3 treated groups were compared to the calculated rates of the control animals used in the previous 
experiments (TrpM4Het and Sarm1Het). After a Shapiro-Wilk test it can be assumed that all data sets are 
normally distributed. For statistical analysis we used two-way ANOVA. * p < 0.05, ** p < 0.005.  
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Interestingly, the decrease in fragmentation events in presence of CI3 was reflected in the 
increase of morphological recovery (see Figure 18(F)). As mentioned above, there are several 
recovery processes possible. The sole morphological recovery of swollen axons to normal 
appearing axons without a change in intra-axonal calcium concentration was increased 
significantly under CI3 treatment (CI3-MR: 0.16 ± 0.04), whereas it remained low in the vehicle 
treated groups (veh-MR: 0.05 ± 0.02), similar like the morphological dynamic rates of the control 
population (control-MR: 0.03 ± 0.02). The rate of calcium decrease was in contrast not affected 
by the treatment. The rates of calcium decrease of CI3 treated group (CI3-CD: 0.19 ± 0.05) and 
vehicle treated group (veh-CD: 0.16 ± 0.04) were in the same range as of the control 
populations (control-CD: 0.25 ± 0.05).  
 
4.4.2 Composition of infiltrating immunes cells in calpain inhibitor treated animal 
in acute EAE is unchanged 
 
Since calpain was inhibited with a pharmaceutical drug, we cannot exclude that the drug also 
has effects on the infiltrating immune cells that could lead to secondary neuroprotection. To 
address this question, we used the dorsal segments of the lumbar spinal cord that was used for 
imaging and investigated those for lesion load and composition of infiltrating immune cells.  
The lesion load was determined as percentage of area within the white matter that is infiltrated 
with Neurotrace positive cells. In Figure 19(B) the values are represented as the mean ± SEM. 
There is not a significant difference detectable between the CI3 treated (38.33 ± 5.82 %) and 
the vehicle treated group (30.43 ± 4.31 %).  
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Figure 19 (previous page). Distribution of CD3+ and Iba+ cells within acute EAE lesions in animals acutely 
treated with Calpain inhibitor 
A) Representative images of nuclei infiltration (stained with Neurotrace640/669), T cells (CD3+ 
staining) and microglia (Iba1+ staining) within acute lesions of imaged animals that were treated either with 
CI3 or with vehicle. B) Lesion load as fraction of area occupied by infiltrating cells within the white matter 
(vehicle: n = 6, CI3: n = 8). C) Density of Iba positive cell within an EAE lesion in number/mm
2
 (vehicle: n = 5, 
CI3: n = 8). D) Density of CD3 positive cells within an EAE lesion in number/mm
2
 (vehicle: n = 5, CI3: n = 8). 
No statistical difference was detected using two-sided student’s t test after confirming normal distribution 
using Shapiro-Wilk test.  
 
Through immunohistochemistry we analyzed the infiltration density of CD3 positive T cells and 
Iba1 positive microglia within the lesions. The results from the quantification are summarized in 
Figure 19(C) and 19(D). The mean density of Iba1 positive cells in vehicle treated animals is 
1671 ± 356 cells/mm2, comparable to the mean density of Iba1 positive cells observed in CI3 
treated animals (1949 ± 464 cells/mm2). The density of CD3 positive cells in vehicle treated 
animals (468 ± 128 cells/mm2) is not significantly different from the density observed in CI3 
treated animals (285 ± 59 cells/mm2). Since there was no significant difference visible, it is likely 
that calpain inhibition does not affect the fragmentation rate via immunomodulatory 
mechanisms. After applying Shapiro-Wilk test it can be assumed that all data sets are normally 
distributed. Therefore, I applied the two-sided unpaired student’s t test for statistical analysis.  
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4.4.3 Long term treatment with calpain inhibitor does not ameliorate disease 
progression 
 
To determine if a long-term treatment with CI3 would ameliorate the clinical disease 
progression, we implanted osmotic pumps that allowed a continuous treatment for 7d 
intrathecally. C57/Bl6 mice were immunized with MOG and their disease development was 
observed daily. Mice that showed their first clinical symptoms (onset of EAE) were randomly 
assigned a pump filled either with CI3 or vehicle. The pump was implanted one day after onset 
and left one week for treatment. The overall clinical course is shown in Figure 20(B).  
 
Figure 20. Long-term treatment with calpain inhibitor: EAE disease course and axonal morphology 
A) Experimental timeline. One day after EAE onset animals were implanted randomly with either with 
vehicle or CI3 filled osmotic pumps. B) Clinical disease course is not influenced by long-term treatment with 
CI3 (vehicle: n = 4, CI3: n = 5; 2way ANOVA, p=0.7815). C) Distribution of axonal stages within EAE lesions 7 
days after treatment (vehicle: n = 4, CI3: n = 5).  
 
Since we were not able to observe a reduced disease severity due to treatment with CI3, we 
investigated the EAE lesions from these mice for axonal damage within lesion. The results are 
displayed in Figure 20(C). Although we observed an effect of calpain inhibition in acute EAE in 
vivo, there were no changes detectable after long term treatment with CI3 with an osmotic 
pump. The distribution of normal appearing axons in the vehicle group (55.39 ± 2.62 %) is very 
similar as observed in the CI3 treated group (56.19 ± 2.92 %). I observed in both groups similar 
numbers of swollen axons (vehicle: 3.13 ± 1.61 % vs. CI3: 4.74 ± 3.15 %) and fragmented 
axons (vehicle: 39.07 ± 5.81 % vs. CI3: 41.47 ± 3.21 %). No statistical significant difference 
could be detected using chi-square test (χ2=0.303, p=0.8594).
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5  Discussion 
5.1 Key findings 
 
Axonal degeneration critically determines the long-term consequences of neuroinflammatory 
lesions. In previous works, it was already shown that in vivo imaging is an excellent tool to study 
axonal degeneration during neuroinflammation (Kerschensteiner et al., 2005; Nikić et al., 2011; 
Sorbara et al., 2012). These studies revealed that axons in experimental and human 
neuroinflammatory lesions undergo focal axonal degeneration and identified the intraaxonal 
accumulation of calcium as a key determinant of axonal fate. In this study, I examined by in vivo 
2 photon imaging how dysregulated calcium levels could trigger axonal dysfunction and 
subsequent fragmentation. I identified a potential therapeutic target within this 
neurodegenerative mechanism. Based on the results that I obtained in this thesis the following 
conclusions can be drawn: 
 Wallerian degeneration-like pathway appears not to be involved in the axonal 
fragmentation process in acute EAE lesions. Neither the lack of Sarm1 nor the 
presence of the Wlds protein could prevent focal axonal degeneration in EAE 
lesions, although they did effectively limit Wallerian degeneration after axon 
transection in the same axon population. As a result, neither genetic manipulation 
affected the acute or chronic course of EAE.  
 Axonal fragmentation can be reduced in vivo in acute EAE by inhibition of calpain, 
a calcium activated non-lysosomal protease. This treatment did not affect immune 
cell infiltration in the studied acute EAE lesions. This suggests that calpain 
inhibition could act as an axonprotective mechanism in neuroinflammatory lesions. 
Although we have yet to identify a suitable therapeutic application protocol that 
results in long term axonal protection. 
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5.2 Using in vivo imaging to study the mechanisms involved in axonal 
degeneration in an animal model of MS 
 
In this work, I collected data for the most part by using a two-photon laser scanning microscope 
in living transgenic mouse lines that expressed a FRET-based calcium sensor in a large subset 
of their neurons. In vivo multiphoton imaging has been succeeding as an experimental 
paradigm, with its advantages of imaging in a living organism under mostly intact and 
physiological conditions. Using multiphoton imaging, we gain insights in dynamic processes in 
deeper layers of the CNS. However, there are the risks of non-linear toxicity and tissue damage 
by linear heating. These potential problems can be reduced by adjusting laser power, imaging 
duration and repeats. 
In our lab, we established the calcium measurement with Thy1-CerTNL15 transgenic mouse 
strain that showed a stable expression of the sensor CerTNL15 driven in a large subset of 
neurons already around birth (Heim et al., 2007). The two fluorophores Cerulean and Citrine are 
linked through a sequence of fast chicken skeletal muscle troponin C, that allows FRET after a 
conformational change induced by calcium binding. The skeletal muscle protein Troponin was 
chosen because no other function is known besides being involved in skeletal muscle 
contraction. With this choice of linker, the sensor does not interfere with endogenous cell 
mechanisms and the sensor itself is not uncontrollably modified by cellular interaction, thereby 
minimizing the risk of false positive intensity change (Direnberger et al., 2012). My colleague 
Minh Schumacher could exclude that the sensors function was diminished by pH change that 
occurs in tissue acidosis or by direct oxidation via ROS/RNS; both are common in immune-
mediated neurodegenerative models (Schumacher, 2016).  
CerTNL15 is reported to be expressed brightly and homogeneously throughout the whole 
neuron as well as its axons and dendrites (Heim et al., 2007). We were able to trace single 
axons along distances >100 µm and over time for several hours and identify their morphological 
changes during degeneration. Nevertheless, due to resolution limits, there is still remaining 
doubt if axons that we identify as fragmented are actually disassembled, or if the observed 
swollen bodies are still undetectably connected. This could be resolved with e.g. EM. With 
suitable control groups, I could minimize the measurement errors due to differences in 
anesthesia and vital functions, surgical trauma and microscope setup. CerTN responds linearly 
to cytosolic calcium concentration within physiologically relevant ranges. Therefore, it is a 
suitable sensor for measuring calcium levels. To increase validity of calcium readouts and as 
established in previous experiments, I decided to determine a cut-off to robustly distinguish 
physiological calcium levels from pathologically increased ones in a binary fashion. This cut-off 
value is based on the mean YFP/CFP intensity ratio obtained from axons of healthy CerTNL15 
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mice, added the three-fold standard deviation. Because CerTNL15 naturally competes for 
calcium binding, it inherently is also a calcium buffer. However, in our experimental paradigm, 
its buffering capacity is neglectable, since we observe up to 4-fold intensity ratio changes that 
persist over time in axons. Using the cut-off and the previously described classification of axon 
morphology (Nikić et al., 2011) I was able to reproduce the previous observations on axonal 
populations, calcium levels and transition rates using the similar methods.  
One major drawback of assessing dynamic transitions in vivo is the low sample size that we 
were able to collect due to my specific question. The efficiency of this experimental approach 
has been proven not to be optimal. To reduce variance in the differentially active 
neuroinflammatory lesions, I decided to use strict inclusion criteria and only evaluate mice, in 
which I could track at least 25 intact axons with pathologically increased calcium levels over the 
entire imaging period for reliable statistical analysis. Nevertheless, in some cases the variance 
in the calculated transition rates was large. In case of TrpM4, Sarm1 and ΔNLS groups, not 
enough animals passed the criteria, leaving us with inconclusive results. In case of the calpain 
group we could include enough animals for statistical analysis and could observe a significant 
reduction in fragmentation rate, despite large variance.  
In comparison to previous studies on neurodegeneration in EAE, I could resolve the fate of 
single axons within acute EAE lesions in various conditions, e.g. genetic manipulation or under 
calpain inhibitor treatment in real-time. Using in vivo 2-photon microscopy allows us to gain 
further insights into the mechanisms of neurodegeneration in EAE, since we are able to study 
dynamic behavior of single axons regarding their morphology and cytosolic calcium 
concentrations.  
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5.3 Wallerian degeneration-like mechanisms are likely not involved in 
axonal fragmentation in acute EAE 
 
I investigated the role of Wallerian-like degeneration elements in EAE lesions through well-
known transgenic models that delay WD. Both Sarm1 and WldS affect the classical WD 
pathway. However, the exact connection between these two mediators is not fully understood. 
These molecules have in common that both of them influence the NAD biosynthesis and it is 
proposed that they carry out their protection through reducing the NAD depletion in injured 
axons.  
In the past, several studies investigated the effect of Wlds in MOG peptide induced EAE. Two 
studies with WldS mice observed a modest delay of EAE onset and a modest attenuation of 
neurological disability accompanied by reduced demyelination and axonal loss (Chitnis et al., 
2007; Kaneko et al., 2006), without altering immune infiltration. This study found that WldS 
exerts its neuroprotective effect either through decreasing the numbers of activated 
macrophage/microglia (Chitnis et al., 2007) or through maintaining neuronal NAD levels that 
can be simulated by administration of the NAD biosynthesis precursor NAM (Kaneko et al., 
2006). On the other hand, in a more recent study (Singh et al., 2017) no striking differences 
were observable in EAE severity after MOG-induced EAE in WldS mice. This study observed a 
moderate decrease in Wallerian degeneration identified through immunoreactivity against NPY-
Y1R serum in the acute stages of EAE and through increase of NAD levels in spinal cords of 
WldS animals with EAE compared to WT. In line with the results of my study, the degree of 
inflammation and demyelination was comparable throughout the EAE disease stages. The net 
axonal loss was similar in the chronic EAE in both groups. In our study, we used an even 
stronger WldS mutant that is lacking the nuclear localization sequence (ΔNLS) and thereby 
retargeting the mutant protein from the nucleus to the cytosol. Transgenic mice overexpressing 
ΔNLS-WldS show an even more robust delay of Wallerian degeneration after a nerve lesion 
(Beirowski et al., 2009). Axon preservation in ΔNLS-WldS lasts for up to 7 weeks after lesion, 
whereas in mice overexpressing the nuclear version WldS in same quantities the axons are 
preserved only up to 4 weeks.  
If axonal degeneration in EAE was, even if only partially, driven by a Wallerian-like degenerating 
pathway, ΔNLS-WldS mice should exhibit an even stronger protection from axonal loss and 
present with an increased attenuation of disease pathology. However, the ΔNLS-WldS mice in 
our EAE experiments neither showed a delayed disease onset nor a reduction in their clinical 
disability. Furthermore, in the acute phase of the disease we could not observe a difference in 
the numbers of swollen or fragmented axons within the active lesion. WldS is a gain-of-function 
mutation and its exact protective mechanism is still elusive. There are reports that WldS, besides 
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substituting Nmnat2, possesses increased calcium buffering capacity. We could however not 
observe any changes in intra-axonal calcium concentration in ΔNLS-WldS mice, suggesting that 
WLD pathways show no influence on calcium in neuroinflammatory axon degeneration, neither 
“upstream” nor “downstream” of calcium elevation. 
In contrast to WldS, Sarm1 is not formed by spontaneous mutation and its deletion shows even 
a more persistent axonal protection than WldS (Gilley et al., 2017). In our study, mice of the 
Sarm1 groups had a tendency to higher overall disease severity compared to the ΔNLS-WldS 
groups, but lack of Sarm1 did not attenuate the clinical symptoms. Examining lesion load, axon 
pathology and calcium levels, I was not able to observe a significant difference.  
In the past years, new players were identified that play a role in Wallerian-like or WLDS-sensitive 
axon disassembly. Thanks to mutagenesis screens and injury assays, a novel mediator of axon 
death was found in drosophila (Neukomm et al., 2017). The appropriately named Axundead 
(axed) mutant saves axons from degeneration after activation of dSarm signalling, loss of 
Nmnat, axotomy and all three combined. Thereby axed lies downstream of dSarm. It is 
noteworthy, that axed mutant axons retain their circuit functionality after axotomy, indicating a 
long-term functional preservation. Based on the strong conservation of dSarm/Sarm1 pathway it 
is likely that a mammalian homolog for axed will be soon identified. According to our results with 
Sarm1-/-, axed is however probably not a good candidate for intervention therapies in 
neuroinflammatory conditions, since we did not find any evidence for a critical role of the Sarm1 
pathway. 
In summary, these results suggest that delaying Wallerian degeneration-like mechanisms does 
not halt axonal fragmentation in acute EAE. However, Wallerian degeneration might be involved 
in secondary degenerative processes. It is supposed that the clinical course of multiple sclerosis 
runs through several phases, every phase sensitive to different influences. In the initial phase, 
inflammation is the dominant factor (Hasseldam and Johansen, 2010), which is responsible for 
relapses in MS. Axonal degeneration conditioned by the amount of prior disease activity drives 
persistent neurological disability in the later, chronic phases, even in absence of active 
inflammation (Coles et al., 1999). Although there is axon damage already present in early 
phases of MS (Dziedzic et al., 2010; Filippi et al., 2003), it appears that another mechanism 
distinct from WD drives this axonal loss. Wallerian-like degeneration might however be rather 
involved in a process with much slower kinetics, which could apply in the progressive variants of 
MS, thereby contributing to the increasing permanent disability. 
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5.4 Effect of TrpM4 deficiency in acute EAE require further study 
 
In my study, loss of TrpM4 showed no effect on disease severity as it was described in a 
previous study of TrpM4-/- in EAE (Schattling et al., 2012). Here, TrpM4+/- x CerTNL15 were 
used as the control group to the knockout mice. As I showed that TrpM4+/- x CerTNL15 animals 
behave like wildtype (WT) CerTNL15 mice in several features, the different outcome cannot be 
explained by the different choice of control group. However, the reduction of disease severity is 
more prominent in the later chronic phase of EAE in the study of Schattling et al.. Additional 
experiments could reveal if the lack of TrpM4 has neuroprotective influence on later timepoints. 
In this study, my interest focused on the effect of TrpM4-/- in the acute phase of disease, in 
which Schattling et al. could not detect any difference between TrpM4-/- and WT group. In their 
study they recorded TrpM4-dependent cation currents in hippocampal-derived cells. A potential 
difference between WT and TrpM4-/- cells was only detectable after previous glutamate 
incubation. Assuming no glutamate-induced excitotoxicity is involved in the acute phase of EAE, 
then the lack of TrpM4 could exert its neuroprotective effect in a different setting which might be 
more glutamate-dependent, as in the later chronic phase, in which Schattling et al. indeed found 
an ameliorating effect of TrpM4-/-. One explanation why I observed a different clinical EAE 
progression in TrpM4-/- mice might be that rather astrocytic TrpM4 is influencing EAE than 
axonal TrpM4. TrpM4 expression is increased in active-demyelinating white matter brain lesions 
of MS patients (Schattling et al., 2012) which lead to the conclusion that axonal TrpM4 
overexpression might lead to axonal damage in EAE. Since the animals used in Schattling and 
in this thesis are global knock outs the TrpM4 deficiency is not limited to the axons but extents 
also to other cell types like astrocytes and immune cells. Recent findings revealed that TrpM4 
and Sur1 are de novo upregulated in injury and disease especially in astrocytes and form 
heteromeric channels (Makar et al., 2015). The sulfonamide glibenclamide, which is widely used 
in Type II diabetes treatment, acts through inhibition of Sur1. Both subunits, Sur1 and TrpM4, 
are required for the manifestation of the pathological effects by forming a heteromer consisting 
of the regulatory subunit Sur1 and the pore-forming subunit TrpM4 (Woo et al., 2013). In 
another study (Gerzanich et al., 2017), the authors found that astrocytes are the predominant 
cell type that upregulates the heteromeric channel TrpM4-Sur1 in both chronic EAE and MS 
lesions. The ablation of Abcc8, which encodes the TrpM4 channel, decreases the amount of 
multiple pro-inflammatory and pathogenic mediators that are secreted by astrocytes in lesions. 
These findings support our observation that TrpM4 deficiency had no influence on the 
fragmentation rate in axons in acute EAE lesions. Since TrpM4 is known to be involved in 
edema development (Simard et al., 2009; Walcott et al., 2012), it is surprising that we did not 
observe a reduction in the swelling rate in TrpM4-/-. There might be compensatory mechanisms 
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involved that at least in part replace the function of TrpM4 channels or TrpM4 overexpression 
after injury is rather associated with astrocytes than axons like the study of Gorse et al. shows 
(Gorse et al., 2018). However, our data on the influence of TrpM4-/- is still preliminary, and 
more experimental data needs to be conducted to be able to verify these observations. 
Moreover, to strengthen the significance of our experimental data a reasonable control 
experiment (like the dorsal hemisection of the spinal cord as model of spinal cord injury to test 
the neuroprotective effects of Sarm1-/- and ΔNLS-WldS) has to be developed that demonstrates 
the neuroprotective potential of TrpM4-/- as it was shown in previous studies (Cho et al., 2014; 
Leiva-Salcedo et al., 2017; Makar et al., 2015; Schattling et al., 2012).   
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5.5 Calpain inhibition reduces axonal fragmentation in acute EAE in vivo 
 
Through inhibition of calpain via Calpain Inhibitor III we could significantly reduce the 
fragmentation rate in vivo in acute EAE lesions. By examining the immune cell composition, we 
could exclude an effect of the drug on immune cell infiltration. To validate calpain inhibitor 
treatment, we treated mice immunized with recombinant MOG over 7 days either with calpain 
inhibitor III or with vehicle. Although we were not able to reduce disease symptoms or improve 
axonal morphology with this long-term treatment, calpain is highly likely to be involved in the 
fragmentation processes in active EAE lesions.  
Calpain inhibitor III has limited solubility in DMSO and therefore the resulting treatment 
concentration via the osmotic pump might be below the effective concentration, as its release 
from the pump is limited to a set flow rate. Other studies using the same calpain inhibitor 
showed that this drug given i.p. is an effective long-term neuroprotectant for axonal injury (Ai et 
al., 2007). Hassen et al. confirmed the ability of calpain inhibitor for long-term neuroprotection. 
They treated mice i.p. prior to and after EAE onset with another calpain inhibitor, CYLA that is 
able to cross the BBB and they observed a reduction of disease severity regarding 
inflammation, demyelination and axonal injury in both treatment groups (Hassen et al., 2008). In 
our treatment paradigm during in vivo imaging sessions, a higher total concentration of the drug 
could be reached by bath incubation, which might explain the significant amelioration of axon 
fragmentation that we could detect in these experiments. Calpain inhibitor III is used as 
treatment option in many different injury or neurodegeneration models (Ai et al., 2007; Crocker 
et al., 2003; Kawamura et al., 2005; Kunz et al., 2004; Ono et al., 2016; Samantaray et al., 
2013; Thompson et al., 2010). We chose this type of calpain inhibitor based on the positive 
treatment outcome on axons in a contusion model (Williams et al., 2014). 
Calpain inhibitor III mostly targets calpain, in contrast to other compounds that inhibit caspases 
and other proteases. Nevertheless, cathepsin B is a side target of calpain inhibitor III (Siklos et 
al., 2015). By using a pharmaceutical inhibition, we cannot exclude that the observed effects are 
results from inhibition of other molecules. 
Moreover, calpain is a very potent protease that is involved in several pathways (for review, see 
(Goll et al., 2003)). Its cleavage products are involved even in competing mechanisms. For 
instance, calpain activation can inhibit apoptosis by cleaving members of the caspase family 
thereby blocking caspase-3 activation (Chua et al., 2000), but under other conditions it cleaves 
pro-caspase 3, thereby triggering programmed cell death (Cheng et al., 2018). Calpain 
activation is involved throughout the development of the CNS (Arthur et al., 2000) and recent 
work suggests that calpains are important for adult neurogenesis as well (Machado et al., 
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2015). It can be even discussed that synaptic plasticity and neurodegeneration share common 
signaling pathways including histone acetylation and deacetylation and mTOR signaling 
(Baudry and Bi, 2016). The controlled activation of calpain under physiological conditions is e.g. 
involved in synaptic function and memory formation (Liu et al., 2008). In pruning, regrowth, but 
also in cell death calpain has the same substrates: structural and scaffolding proteins, enzymes 
and receptors. Among others, the extent of calpain activation is determining which process is 
executed (Gan-Or and Rouleau, 2016). Several isoforms of calpain exist that exhibit partly even 
opposite functions. For example, calpain-1 is rather associated with induction of LTP, whereas 
calpain-2 is involved in limiting this LTP and is involved in neurodegeneration (Baudry and Bi, 
2016; Wang et al., 2013). These examples lead to the conclusion that calpain can be only a 
potential therapeutic target if its inhibition is specific and coordinated in time and location. To 
achieve this, several questions need to be addressed first. Calpain-2 appears to be a good 
candidate (Baudry and Bi, 2016; Seinfeld et al., 2016; Wang et al., 2018a, 2018b), but other 
calpain isoforms might be still identified.  
A few studies show that calpain expression was increased in activated T cells (Nicole et al., 
2013), and its inhibition in MBP-specific T cells attenuated their encephalitogenicity in RR-EAE 
mice after transplantation (Guyton et al., 2009). To increase the validity of our finding that 
neuroprotection via CI3 is inherent to neurons, the calpain inhibition should be more specifically 
targeted. This can be achieved by viral overexpression of the endogenous calpain inhibitor 
calpastatin. In an optical nerve crush model, the neuroprotective potential of calpastatin 
overexpression was shown (Yang et al., 2013). The viral construct contains a CMV promotor 
which targets expression injected in the CNS not only to neurons, but also to other cell types 
like astrocytes. To overcome this unspecificity, several ways are possible: either through 
injection of the construct in DRGs, or by replacing the CMV promotor with a hSyn that drives 
expression specifically to neurons.  
Supposing that inhibition of calpain within the neurons indeed restricts degeneration, the 
mechanism driving axonal degeneration in acute EAE lesions remains elusive. Since with 
calpain many destructive pathways converge, it might be still an optimal target for 
neuroprotection (see Figure 21). Wallerian-like degeneration and TrpM4-mediated excitotoxicity, 
that both are described in this thesis, involve at some point the activation of the neuronal death 
executor, calpain. There are many studies that show that calpain inhibition attenuates axonal 
damage in different disease models like AD (Rao et al., 2008, 2014), PD (Diepenbroek et al., 
2014), ALS (Rao et al., 2016), traumatic brain injury (Ma et al., 2012; Schoch et al., 2012), ON 
(Hoffmann et al., 2013) and MS (Hassen et al., 2006, 2008). Although it is not clear what 
initiated the axonal disassembly, by inhibiting a downstream executor we are able to prevent 
further degeneration.  
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Figure 21: Schematic overview of possible calpain-dependent neurodegeneration pathways. 
Depicted are some of the possible, both physiological and pathological cell death pathways 
(autophagy, necrosis, apoptosis) and necroptosis and pathways that lead to axonal damage (axotomy, 
excitotoxicity). All of them involve in the later stages an increase in intracellular calcium and the 
overactivation of calpain which if not inhibited lead to the excessive proteolysis of cytoskeletal proteins. 
Inhibition of calpain by activation of the endogenous inhibitor calpastatin or pharmacological intervention 
potentially is axonprotective since it prevents the uncontrolled breakdown of the cytoskeleton. 
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5.6 Relevance for MS 
 
In the recent decades, the focus of MS research shifted to understanding the 
neurodegenerative arm of the disease. As discussed earlier, the current available DMT mostly 
aim to positively influence the disease outcome by modifying the immunological component, 
they have only limited effect on the preservation of neuronal structure and function, and thereby 
on the long-term outcome (Graetz et al., 2018). Instead of only focusing solely on the 
inflammatory processes, treatment strategies might be more promising, that target the 
neurodegenerative processes as well. Potential neuroprotective agents should either promote 
the endogenous repair mechanisms, target survival pathways or inhibit the neurodegenerative 
cascade, but for development of a suitable treatment, the processes underlying the axonal loss 
in EAE and MS need to be understood. Using 2 photon imaging and transgenic mouse lines 
FAD could be identified in lesions in EAE, an established animal model for MS (Nikić et al., 
2011) and pathological increased intra-axonal calcium correlated with higher risk of axonal 
fragmentation. Since axonal abnormalities resembling FAD were found in MS biopsies as well, it 
can be assumed that calcium dysregulation is involved in MS as well. One possible point of 
action for neuroprotection is to decrease ion imbalance (specifically Ca2+) within axons by 
blockage of ion channels. Voltage-gated and acid-sensing ion channels (ASICs) are discussed 
among others to contribute to ion dysregulation observed in EAE and MS (Ingwersen et al., 
2018; Ortega-Ramírez et al., 2017). Despite investigating several ion channels, a clear 
candidate could not be isolated so far. Another neuroprotective approach is rescuing neurons 
and their processes from oxidative stress by scavenging ROS and RNS with antioxidative 
reagents (van der Goes et al., 1998; Ghafourifar et al., 2008; Nikić et al., 2011).  
Based on the previous findings, my work further investigated which possible destructive 
mechanisms are activated by the increased calcium levels. Calpain seems a promising 
therapeutic target for neuroprotective strategies. In several murine models of 
neurodegeneration, the inhibition of calpain with synthetic inhibitor peptides (SNJ-1945 used in 
MS model (Trager et al., 2014) and cortical impact traumatic brain injury (Bains et al., 2013); 
MDL-28170 used in spinal cord injury model (Brocard et al., 2016); Calpeptin used in EAE 
model (Das et al., 2013; Guyton et al., 2010)) or via overexpression of the endogenous 
calpastatin (Diepenbroek et al., 2014; Schoch et al., 2012; Ma et al., 2012; Rao et al., 2014, 
2016; Yang et al., 2013) was found to successfully attenuate degeneration. However, a long-
term treatment with calpain inhibitor using intrathecal osmotic pumps showed that the delivery 
of intervention is a critical point that needs in itself further development. 
In contrast to other neuroprotective approaches, calpain as a target has a major advantage. 
Different neurodegenerative processes like excitotoxicity, apoptosis, necrosis and others lead to 
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the overactivation of calpain as the executor of axonal disintegration. Targeting calpain might 
present a promising strategy to delay neuronal death, axonal fragmentation or to promote 
recovery processes without the full understanding of the disease causes, which needs further 
investigations and better disease models.    
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5.7 Concluding remarks 
 
Since MS was for the first time recognized as disease entity back in the 19th century, the 
disease remains enigmatic, particularly because it manifests in many different forms. No person 
diagnosed with MS will have the same clinical course, which makes it even harder to grasp the 
nature of this disease. Over the years, there have been several debates about the primary 
cause: traditionally MS was seen as an autoimmune disease of the CNS in which aberrant 
immune cell enter the CNS through a broken BBB and turn against their own body and attack 
CNS components like the insulating myelin. Myelin loss and aggressive interaction of activated 
immune cells leads to neurodegeneration (outside-in model). Other clinical observations lead to 
the competing inside-out model: Primary degeneration and/or oligodendrocyte death initiate 
autoimmune and inflammatory response through release of antigenic proteins and lipids. There 
is evidence supporting both models, but since the solely use of DMT does not halt disability 
progression in most of MS patients, the development of additional neuroprotective strategies is 
in any case necessary. Therefore, MS research in the past years shifted partly to investigate the 
neurodegenerative part of the disease. 
In my thesis I investigate several mechanisms of axon destruction that are presumed to be 
involved in neurodegeneration in MS. Since my work is a follow up of my colleagues Ivana Nikic 
and Minh Schumacher it was first necessary to show that I can reproduce their findings with the 
methods they established. In the first part of my work, I show that I could successfully reproduce 
the observation of calcium dysregulation in early axonal stages within active EAE lesions. By 
following the fate of these axons over a longer period, I was able to obtain similar transition 
rates. Additionally, by reproducing the previous findings I could show that the control animals for 
the transgenic experiments are behaving similar to the WT-CerTNL15, thereby justifying the use 
of heterozygous TrpM4 and Sarm1 as control mice. 
I showed that both, Sarm1-/- and the WldS mutant, which are known to delay significantly 
Wallerian-like degeneration after spinal cord injury, are not able to significantly halt focal axonal 
degeneration in acute EAE lesions. This does not exclude that the Wallerian degeneration-like 
pathways are involved in later phases or in sites distant to the actual lesions as a form of 
secondary degeneration.  
Finally, I demonstrated that pharmacological inhibition of calpain reduces fragmentation rates in 
acute EAE. As a converging point for several distinct degenerative mechanisms, calpain 
inhibition would overcome our current lack of understanding the exact cause of 
neurodegeneration in MS. Furthermore, a more effective targeting strategy than the intrathecal 
delivery need to be developed for long-term protection. Better treatment strategies that target 
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neuroprotection and remyelination besides immunomodulation promise MS patients and their 
families to fundamentally improve quality of life and reduce their constant anxiety of what this 
unpredictable disease might bring them. 
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